SLC inhibitors and uses thereof
Compounds targeting SLC15A proteins address the dysregulation of immune system pathways, effectively treating autoimmune disorders and facilitating research on SLCs.
Patent Information
- Application Number
- PCT/US2026/028380
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
The dysregulation of pathogen-recognition pathways in the innate immune system, particularly the aberrant activation of endolysosomal toll-like receptors, leads to excessive responses associated with autoimmune disorders like systemic lupus erythematosus and inflammatory conditions, necessitating the development of specific therapeutics targeting the SLC15A4 transporter.
Compounds are developed to inhibit the SLC15A family of proteins, specifically SLC15A3 and SLC15A4, which are effective in modulating these pathways and treating associated autoimmune disorders.
The compounds effectively inhibit SLC15A proteins, providing therapeutic benefits for autoimmune disorders and offering tools for studying SLCs in biological and pathological phenomena.
Smart Images

Figure US2026028380_19112026_PF_FP_ABST
Abstract
Description
SLC INHIBITORS AND USES THEREOFTECHNICAL FIELD
[0001] The present disclosure relates to compounds and methods useful for inhibiting Solute Carrier (SLC ) peptide transporters. The disclosure also provides pharmaceutically acceptable compositions comprising compounds of the present disclosure and methods of using said compositions in the treatment of various disorders.BACKGROUND
[0002] Dysregulation of pathogen-recognition pathways of the innate immune system is associated with multiple autoimmune disorders. Due to the intricacies of the molecular network involved, the identification of pathway- and disease-specific therapeutics has been challenging.
[0003] Despite tight regulatory mechanisms, aberrant activation of these pathways by endogenous ligands or mutations in key regulatory components lead to excessive responses that are causatively linked to several autoimmune conditions. In particular, sensing of nucleic acids by endolysosomal toll-like receptors (TLRs) is thought to be critically involved in the etiology of systemic lupus erythematosus and related autoimmune diseases as well as inflammatory conditions. See e.g., G. J. Brown et al., Nature 605, 349-356 (2022) and S. Fillatreau, B. Manfroi, T. Dorner, Nat Rev Rheumatol 17, 98-108 (2021).
[0004] Both human genetic and mouse studies have unequivocally identified the lysosomal solute carrier transporter SLC15A4 and transcription factor IRF5 as components essential for mediating disease development downstream of TLRs. See e.g., T. Ban, G. R. Sato, T. Tamura, Int Immunol 30, 529-536 (2018). There is a need for small molecule inhibitors of SLCs (e.g., SLC15).SUMMARY
[0005] It has now been found that compounds of the present disclosure, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of certain members of the SLC family of proteins. Compounds of the present disclosures, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of the SLC15A family of proteins, (e.g., SLC15A3, and / or SLC15A4). In certain embodiments, the disclosure provides for compounds of the formulae presented herein.
[0006] Compounds of the present disclosure, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with modulating SLC and more particularly modulating the SLC 15 A family of proteins, (e.g., SLC 15 A3, and / or SLCL5A4). Such diseases, disorders, or conditions include those described herein.
[0007] Compounds provided by this disclosure are also useful for the study of SLCs in biological and pathological phenomena; the study of intracellular signal transduction pathways occurring in bodily tissues;and the comparative evaluation of new SLC inhibitors, signaling pathways, and cytokine levels in vitro or in vivo.DETAILED DESCRIPTION1. General Description of the Disclosure:
[0008] In certain embodiments, the present disclosure provides a compound of formula I:Ior a pharmaceutically acceptable salt thereof, wherein each of Ring B, R1, R3, R5, R6, Z1. and Z2are as defined below and described in embodiments herein, both singly and in combination.
[0009] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant, or diluent.
[0010] In some embodiments, the present disclosure provides a method of treating a SLC-mediated disease, disorder, or condition comprising administering to a patient in need thereof, a compound of formula1, or a pharmaceutically acceptable salt thereof.2. Compounds and Definitions:
[0011] Compounds of the present disclosure include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001.
[0012] As used herein, designations “S” or “R” or “abs” denote a stereogenic center where the absolute configuration is known. Designation “or”, such as “orl”, “or2” etc., denotes a stereogenic center where theabsolute configuration is not known, but is still a single stereoisomer of a fixed configuration. The designations “and” orsuch as “andl” or “&1”, are used interchangeably and denote a mixture of stereoisomers, e.g., a pair of enantiomers or diastereomers, with respect to the designated stereogenic center.
[0013] Compound structures shown throughout the present specification and in the examples or claims may contain single stereocenter with either “S”, “R”, “abs”, “or”, “and” ordesignation at said stereocenter which indicates the following: compound structures with stereocenter marked with “abs” or “S” or “R” intend to represent stereochemically pure compounds (single stereoisomers, single enantiomers) wherein the marked stereocenter is of the absolute stereochemistry shown in the diagram as in example structures A and B. Compound structures with stereocenter marked with “or” designation, such as “orl”, intend to represent stereochemically pure compounds wherein the stereochemistry at the stereocenter marked with “orl” is either the stereochemistry shown in the diagram or wherein the marked stereocenter has a configuration opposite to what is shown in the diagram, as in example structure C. Compound structures with stereocenter marked withor “and” designation, such as “&1” or “andl”, intend to represent a mixture of R and S-configured stereoisomers (enantiomers), as in example structure D.Single stereocenterA B C Dsingle stereoisomer single stereoisomer mixture of 2 stereoisomers absolute stereochemistry as shown absolute stereochemistry undefined
[0014] Compound structures shown throughout the present specification and in the examples or claims may contain a designation at two (or more) stereogenic centers, which indicate the following: compound structures with certain stereocenters marked with “abs” or “S” or “R” intend to represent compounds wherein the said stereocenters are of the stereochemistry shown in the diagram as in example structures E and F.
[0015] Compound structures which contain “or” designation at certain stereocenters, such as “orl” or, “or2”, are intended to represent compounds wherein the stereochemistry at said stereocenters is either the stereochemistry shown in the diagram or wherein the marked stereocenters have a configuration opposite to what is shown in the diagram, i.e., the absolute stereochemistry at each stereocenter is not known. At the same time, the relative stereochemistry between stereocenters with the same “or” label, such as “orl”, is defined as drawn in the diagram, as in example structure G. The relative stereochemistry between thestereocenters with different “or” labels, such as “orl” and “or2”, is not defined and can be either as drawn in the diagram or can be opposite to what is drawn in the diagram, as in example structure H.
[0016] Compound structures which contain “&” or “and” designations at certain stereocenters, such as “&1” or “andl”, are intended to represent the compound material which is a mixture of R and S-configured stereoisomers with respect to the marked stereocenters. At the same time the relative stereochemistry between stereocenters with the same “&” or “and” label, such as “&1” or “andl”, is defined as drawn in the diagram, as in example structure I.Several stereocenters (exemplified by 2 stereocenters)G Hsingle stereoisomer single stereoisomer single stereoisomer relative stereochemistry as shown relative stereochemistry as shown relative stereochemistry undefined absolute stereochemistry as shown absolute stereochemistry undefined absolute stereochemistry undefinedImixture of 2 stereoisomersrelative stereochemistry as shown
[0017] It is to be understood that compounds with two (or more) stereocenters which have either “or”, “S”, “R” or “abs” designations and do not have “&” or “and” designations at any given stereocenter are single compounds (e.g., a single stereoisomer, single diastereomer or a single enantiomer) rather than mixtures of compounds.
[0018] Compound structures shown throughout the present specification and in the examples or claims may contain an “or”, *’r”, ”s” designation at pseudoasymmetric centers, which indicate the following: compound structures with certain pseudoasymmetric centers marked with “r” or "s” intend to represent compounds wherein the said pseudoasymmetric centers are of the stereochemistry shown in the diagram as in example structure K or L. Compound structures which contain different “or” labels at certain stereocenters, such as “oil” and “or2”, are intended to represent compounds wherein the relative stereochemistry at said stereocenters is either as drawn in the diagram or can be opposite to what is drawn in the diagram, as in example structure M.Stereoisomers in systems with pseudoasymmetric centersK L MSingle stereoisomer Single stereoisomer stereoconfiguration as shown stereoconfiguration undefined
[0019] It is to be understood that compound structures drawn without any indication of stereoconfiguration, that is compound structures drawn with flat bonds to asymmetric or pseudoasymmetric centers, are intended to represent stereoisomers of unknown stereochemistry as well as any mixture thereof, as in example structures N, O, P.any possible stereoisomer or mixture thereof
[0020] It is to be understood that compound structures drawn with stereobonds to asymmetric or pseudoasymmetric centers and without use of any labels at said asymmetric or pseudoasymmetric centers are intended to represent compounds with absolute stereochemistry as shown in the diagram, as in example structures Q, R, S.single stereoisomer with absolute stereochemistry as drawn
[0021] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle," “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest ofthe molecule. Unless otherwise specified, aliphatic groups contain 1-12 carbon atoms. In some embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0022] As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. The term “alkyl” refers to a C1-12 straight or branched saturated aliphatic group. In certain instances, alkyl refers to a C1-8 straight or branched saturated aliphatic group or a C1-6 straight or branched saturated aliphatic group. The term “lower alkyl” refers to a C1-4 straight or branched alkyl group.
[0023] Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl (also referred to interchangeably herein as 2-propyl, iPr, Tr and i-Pr), butyl, isobutyl (also referred to interchangeably herein as 2-butyl, iBu, 'Bu and i-Bu) and tert-butyl (also referred to interchangeably herein as 2-methyl-2-butyl, tBu, 'Bu and t-Bu).
[0024] The term “alkenyl” refers to a C2-12 straight or branched partially unsaturated aliphatic group comprising at least one unsaturated carbon carbon double bond. In certain instances, alkenyl refers to a C2-8 or a C1-6 straight or branched partially unsaturated aliphatic group comprising at least one unsaturated carbon carbon double bond. The term “lower alkenyl” refers to a C2-4 straight or branched partially unsaturated aliphatic group comprising at least one unsaturated carbon carbon double bond. Alkenyl groups include both cis (Z) and trans (E) regioisomers. Exemplary lower alkenyl groups are vinyl, allyl, 2-propenyl,and butenyl isomers (-CH₂CH₂CH=CH₂, -CH₂CH=CHCH₃ and -CH=CH=CH₂CH₃).
[0025] The term “alkynyl” refers to a C2-12 straight or branched partially unsaturated aliphatic group comprising at least one unsaturated carbon carbon triple bond. In certain instances, alkynyl refers to a C2-8or a C1-6 straight or branched partially unsaturated aliphatic group comprising at least one unsaturated carbon carbon triple bond. The term “lower alkynyl” refers to a C2-4 straight or branched partially unsaturated aliphatic group comprising at least one unsaturated carbon carbon triple bond. Exemplary lower alkynyl groups are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, and 3-butynyl.
[0026] The term “haloalkyl” refers to a straight or branched alkyl group that is substituted with one or more halogen atoms. The term “lower haloalkyl’’ refers to a CM straight or branched alkyl group that is substituted with one or more halogen atoms.
[0027] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3.4-dihydro-2 / / -pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).
[0028] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.
[0029] As used herein, the term “bivalent Ci-s (or CM) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
[0030] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., –(CH2)n–, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0031] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0032] The term “halogen” means F, Cl, Br, or I.
[0033] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present disclosure, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
[0034] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, for instance, 5, 6, 9 or 10 ring atoms; having 6, 10, or 14 it electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, triazinyl, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl (i.e., 1,2,3-triazolyl), 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the heteroaromatic ring is fused. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, indolizinyl, isoindolin-1-onyl, l,2-dihydro-3H-pyrrolo[3,4-c] pyridin-3-onyl, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-onyl, imidazo [ 1, 2-a] pyridyl, imidazo [1,5-a]pyridyl, pyrazolo[l,5-a]pyridyl, pyrrolo[l,2-b] pyridazinyl, pyrrolo[l,2-a]pyrimidinyl, imidazo[l,2-b] pyridazinyl, imidazo [1, 2-a] pyrimidinyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
[0035] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, for instance, one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2 / 7-pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in N-substituted pyrrolidinyl).
[0036] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, oxetanyl, azetidinyl,tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6-azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
[0037] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
[0038] As described herein, compounds of the disclosure may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0039] Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; –(CH2)0-4R°; –(CH2)0-4OR°; -0(CH2)o4R°, -O-(CH2)Q-4C(O)OR°; -(CH2)O-4CH(OR°)2; -(CH2)O 4SR°; –(CH2)0-4Ph, which may be substituted with R°; -(CH2)o-40(CH2)o-iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; –(CH2)0-4O(CH2)0-1-pyridyl which may be substituted with R°; -NO2; -CN; -N3; -(CH2)o-4N(R°)2; -(CH2)o^N(R°)C(G)R°; -N(R°)C(S)R°; -(CH2)O-4N(R0)C(0)NR02; -N(RO)C(S)NR°2; -(CH2)O-4N(R°)C(0)OR0;N(RO)N(RO)C(O)R°; -N(R°)N(RO)C(O)NRO2; -N(R°)N(R°)C(O)OR°; -N(R0)C(NR°)N(R°)2; -(CH2)o-4C(O)R°; -C(S)R°; -(CH2)(MC(O)OR°; -(CH2)O^C(0)SR0; -(CH2)O- C(O)OSiRo3; -(CH2)(MOC(O)RO; -OC(O)(CH2)(MSRO; -(CH2)O-4SC(0)R°; -(CH2)O^C(0)NR°2; -C(S)NRO2; -C(S)SR°; -SC(S)SR°, –(CH2)0-4OC(O)NR°2; -C(O)N(OR°)R°; -C(O)C(O)R°; –C(O)CH2C(O)R°; -C(NOR°)R°; –(CH2)0-4SSR°;-(CH2)O-4S(0)2R°; -(CH2)O-4S(0)20R°; –(CH2)0-4OS(O)2R°; -S(O)2NR°2; -(CH2)O-4S(0)R°; -N(R°)S(O)2NR°2; -N(RO)S(O)2R°; -N(OR°)R°; -C(NH)NRO2; –(CH2)0-4P(O)2R°; -(CH2)O-4P(0)R°2; -(CH2)O-40P(0)R°2; -(CH2)O-40P(0)(OR°)2; -SiR°3; -(C1-4 straight or branched alkylene)O-N(R°)2; or -(C1-4 straight or branched alkylene)C(O)O-N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, C1-6 aliphatic, -CH2Ph, -0(CH2)o-iPh, -CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
[0040] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)o_2R*, -(haloR*), -(CH2)o-2OH, -(CH2)o 2OR*, -(CH2)O2CH(OR*)2; -O(haloR’), -CN, -N3, -(CH2)o2C(O)R‘, -(CH2)o2C(O)OH, -(CH2)o-2C(0)OR*, -(CH2)O 2SR*, -(CH2)O 2SH, -(CH2)O2NH2, -(CH2)O2NHR‘, -(CH2)O2NR*2, -NO2, -SiR’s, -OSiR*3, -C(O)SR*, –(C1-4straight or branched alkylene)C(O)OR*, or -SSR* wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C1-4 aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.
[0041] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNl 1S(O)2R”, =NR*, =NOR*, -O(C(R*2))2-3O-, or -S(C(R*2))2-3S-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -O(CR*2)2-3O-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0042] Suitable substituents on the aliphatic group of R* include halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR’), -CN, -C(O)OH, -C(O)OR’, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0043] Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include Rf, -N'R'2, -C(O)Rt, -C(O)ORf, -C(O)C(O)Rf, -C(O)CH2C(O)Rt, -S(O)2Rt, -S(O)2NRf2, -C(S)NRf2, -C(NH)NRf2, or -N(Rt)S(O)2Rt; wherein each R is independently hydrogen, C1-6aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered satur ated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R', taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0044] Suitable substituents on the aliphatic group of R+are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR’), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci-4 aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0045] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19. Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-tolucncsulfonatc, undccanoatc, valerate salts, and the like.
[0046] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci alkyl )4salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
[0047] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, Z and E conformational isomers and Ra(or M) and Sa(or P) atropisomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the disclosure are within the scope of the disclosure. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this disclosure. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.
[0048] The structures as drawn represent absolute configurations unless indicated otherwise. The disclosure contemplates individual enantiomers and diastereomers, enantiomerically enriched enantiomers and diastereomers, and racemic mixtures of enantiomers and diastereomers.
[0049] As used herein, a " SLC inhibitor" is a molecule that reduces, inhibits, or otherwise diminishes one or more of the biological activities of SLC (e.g., facilitating the transport of molecular substrates across biological membranes). Inhibition using the SLC inhibitor does not necessarily indicate a total elimination of the SLC activity. Instead, the activity could decrease by a statistically significant amount including, for example, a decrease of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95% or 100%' of the activity of SLC compared to an appropriate control.
[0050] A compound of the present disclosure may be tethered to a detectable moiety. It will be appreciated that such compounds are useful as imaging agents. One of ordinary skill in the art will recognize that a detectable moiety may be attached to a provided compound via a suitable substituent. As used herein, the term “suitable substituent’’ refers to a moiety that is capable of covalent attachment to a detectable moiety. Such moieties are well known to one of ordinary skill in the art and include groups containing, e.g., a carboxylate moiety, an amino moiety, a thiol moiety, or a hydroxyl moiety, to name but a few. It will be appreciated that such moieties may be directly attached to a provided compound or via a tethering group, such as a bivalent saturated or unsaturated hydrocarbon chain. In some embodiments, such moieties maybe attached via click chemistry. In some embodiments, such moieties may be attached via a 1,3-cycloaddition of an azide with an alkyne, optionally in the presence of a copper catalyst. Methods of using click chemistry are known in the art and include those described by Rostovtsev et al., Angew. Chem. Int. Ed. 2002, 41:2596-99 and Sun etal., Bioconjugate Chem., 2006, 17:52-57.
[0051] As used herein, the term “detectable moiety” is used interchangeably with the term "label" and relates to any moiety capable of being detected, e.g., primary labels and secondary labels. Primary labels, such as radioisotopes (e.g., tritium,32P,33P,3’S, or14C), mass-tags, and fluorescent labels are signal generating reporter groups which can be detected without further modifications. Detectable moieties also include luminescent and phosphorescent groups.
[0052] The term “secondary label” as used herein refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate for production of a detectable signal. For biotin, the secondary intermediate may include streptavidin-enzyme conjugates. For antigen labels, secondary intermediates may include antibody-enzyme conjugates. Some fluorescent groups act as secondary labels because they transfer energy to another group in the process of nonradiative fluorescent resonance energy transfer (FRET), and the second group produces the detected signal.
[0053] The terms “fluorescent label”, “fluorescent dye”, and “fluorophore” as used herein refer to moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength. Examples of fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665), Carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin 343, Cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), Dansyl, Dapoxyl, Dialkylaminocoumarin, 4',5'-Dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, Eosin, Erythrosin, Fluorescein, FAM, Hydroxycoumarin, IRDyes (IRD40, IRD 700, IRD 800), JOE, Lissamine rhodamine B, Marina Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2',4',5',7'-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas Red-X.
[0054] The term “mass-tag” as used herein refers to any moiety that is capable of being uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques. Examples of mass-tags include electrophore release tags such as N-[3-[4’-[(p-Methoxytetrafluorobenzyl)oxy]phenyl]-3-mcthylglyccronyl]isonipccotic Acid, 4’-[2,3,5,6-Tctrafluoro-4-(pcntafluorophcnoxyl)]mcthyl acetophenone, and their derivatives. The synthesis and utility of these mass-tags is described in UnitedStates Patents 4,650,750, 4,709,016, 5,360,8191, 5,516,931, 5,602,273, 5,604,104, 5,610,020, and 5,650,270. Other examples of mass-tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying length and base composition, oligopeptides, oligosaccharides, and other synthetic polymers of varying length and monomer composition. A large variety of organic molecules, both neutral and charged (biomolecules or synthetic compounds) of an appropriate mass range (100-2000 Daltons) may also be used as mass-tags.
[0055] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change in a SLC protein activity between a sample comprising a compound of the present disclosure, or composition thereof, and a SLC protein, and an equivalent sample comprising an SLC protein, in the absence of said compound, or composition thereof.3. Description of Exemplary Embodiments:
[0056] As described above, in certain embodiments, the present disclosure provides a compound of formula I:Ior a pharmaceutically acceptable salt thereof, wherein:R1is halogen, alkoxy, C ycycloalkoxy, haloalkoxy, a C3-7 cycloalkyl, phenyl, cubanyl, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a C5-12 bridged bicyclic carbocyclic ring, or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein each R1is optionally substituted with q instances of R9;q is 0, 1, 2, 3, or 4;each R9is independently hydrogen, halogen, -CN, -OR, oxo, -N(R)2, - C(R)2OR, -S(O)2NR2, -C(O)N(R)2, -C(R)2C(O)N(R)2or an optionally substituted group selected fromCi-6 aliphatic, C1-5cycloalkyl, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Z1is CR2or N; Z2is CR2or N; where at least one of Z1or Z2is not N;R2is hydrogen, halogen, -N(R)2, -OR, or optionally substituted Ci-6aliphatic;Ring B is selected from cubanyl, pyridinone, pyrazolopyridine, indazole, a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orwherein Ring B together with substituent R3is selected from; wherein:X1, X2, X3, and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;Xsis C or N;X9is C or N;R3is an optionally substituted group selected from Cs-ealiphatic; Cz-ealkoxy; Cs-Cecycloalkyloxy; chlorodifluoromethoxy; cycloalkyl substituted methoxy; a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 4-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with s occurrences of R3A;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4taken together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur;each R3Ais independently halogen, OR, cycloalkyl or a mono- or di-C2-6alkyl amino;s is 0, 1, 2, 3, 4, or 5t is 0, 1, 2, 3, or 4;R5is optionally substituted C1-6aliphatic;R6is L-R7; orR5and R6taken together with the nitrogen atom to which they are attached form a 5-7-membered saturated or partially unsaturated monocyclic heterocycle or 8-12-membered saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8;L is a covalent bond or an optionally substituted C1-8bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by -C(R)2-, -Cy-, -N(R)-, -O-, C(O)-, -S-, -S(O)- or -S(O)2-; each -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each R7is independently hydrogen, halogen, -N(R)2, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R8is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R, -C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; ortwo R8together with the atom(s) to which they are attached form a 3-7-membered spiro, fused, or bridged saturated or partially unsaturated monocyclic carbocyclic ring;u is 0, 1, 2, 3, 4, or 5;each R is independently hydrogen, -CN, halogen, or an optionally substituted group selected from Ci-6 aliphatic; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- 10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; ortwo R groups on the same carbon or nitrogen are taken together to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0057] In some embodiments of the compound of Formula (I), R1is halogen, alkoxy, haloalkoxy, a C3-7 cycloalkyl, phenyl, cubanyl, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a C5-12 bridged bicyclic carbocyclic ring, or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein each R1is optionally substituted with q instances of R9;q is 0, 1, 2, 3, or 4;each R9is independently hydrogen, halogen, -CN, -OR, oxo, -N(R)2, C(R)2OR, -S(O)2NR2, -C(O)N(R)2, -C(R)2C(O)N(R)2or an optionally substituted group selected from C1-6 aliphatic, C1-5cycloalkyl, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Z1is CR2or N; Z2is CR2or N; where at least one of Z1or Z2is not N;R2is hydrogen, halogen, -N(R)2, -OR, or optionally substituted C1-6aliphatic;Ring B is selected from cubanyl, a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orH( ^ wherein Ring B together with substituent R3is selected fromx -x,; wherein:X1, X2, X3and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;Xsis C or N;X9is C or N;R3is an optionally substituted group selected from C1-6aliphatic; (S--, alkoxy;cycloalkyloxy: chlorodifluoromethoxy; cycloalkyl substituted methoxy; a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 4-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with s occurrences of R3A;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4are optionally and independently taken together to form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; each R3Ais independently halogen, OR, Ch-ecycloalkyl, or a mono- or di-C2-6alkyl amino;s is 0, 1, 2, 3, 4 or 5;t is O, 1, 2, 3, or 4;R5is hydrogen or optionally substituted C1-6aliphatic;R6is L-R7; orR3and R6taken in combination form a saturated or partially unsaturated monocyclic heterocycle or saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle each of which is optionally substituted with u occurrences of R8;L is a covalent bond or an optionally substituted C1-8bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by -C(R)2-, -Cy-, -N(R)-, -O-, C(O)-, -S-, -S(O)- or -S(O)2-;each -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R7is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R8is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from Ci-galiphatic, Ci-Cshaloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;u is 0, 1, 2, 3, 4 or 5;each R is independently hydrogen, -CN, halogen, or an optionally substituted group selected from Ci-6aliphatic; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur'; a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:two R groups on the same carbon or nitrogen are taken together to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0058] As described above, R1is halogen, alkoxy, C3-7cycloalkoxy, haloalkoxy, a C3-7 cycloalkyl, phenyl, cubanyl, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a C5-12 bridged bicyclic carbocyclic ring, or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein each R1is optionally substituted with q instances of R9.
[0059] In some embodiments, R1is halogen, alkoxy, haloalkoxy, a C3-7 cycloalkyl, phenyl, cubanyl, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a C5-12 bridged bicyclic carbocyclic ring, or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein each R1is optionally substituted with q instances of R9.
[0060] In some embodiments, R1is halogen. In some embodiments, R1is alkoxy optionally substituted with q instances of R9. In some embodiments, R1is haloalkoxy. In some embodiments, R1is C3-7 cycloalkyl optionally substituted with q instances of R9. In some embodiments, R1is phenyl optionally substituted with q instances of R9. In some embodiments, R1is cubanyl optionally substituted with q instances of R9. In some embodiments, R1is a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring optionally substituted with q instances of R9, and having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R1is a C5-12 bridged bicyclic carbocyclic ring optionally substituted with q instances of R9. In some embodiments, R1is a 5-10 membered heteroaryl optionally substituted with q instances of R9, and having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, R1is alkoxy optionally substituted with q instances of R9.
[0061] In some embodiments, R1is a 9 membered heteroaryl optionally substituted with q instances of R9, and having 2 nitrogens. In some embodiments, R1is a 9 membered heteroaryl optionally substituted with q instances of R9, and having 1 oxygen. In some embodiments, R1is pyridinyl optionally substituted with q instances of R9. In some embodiments, R1is thiophenyl optionally substituted with q instances of R9. In some embodiments, R1is oxazolyl optionally substituted with q instances of R9. In some embodiments, R1is isoxazolyl optionally substituted with q instances of R9. In some embodiments, R1is pyrazolyl optionally substituted with q instances of R9. In some embodiments, R1is thiazolyl optionally substituted with q instances of R9. In some embodiments, R1is pyrazolo[l,5-a]pyridinyl optionally substituted with q instances of R9. In some embodiments, R1is benzofuranyl optionally substituted with q instances of R9. In some embodiments, R1is dihyd
[0062] In some embodiments,
[0067] In some embodiments, R1is as depicted in any one of the compounds of Table 1, below.
[0068] In some embodiments, R1is as depicted in any one of the compounds of Table 1A, below.
[0069] In some embodiments, R1is as depicted in any one of the compounds selected from 1-151, 1-165,1-282, 1-283, 1-293, 1-309, and 1-350.
[0070] As described above, q is 0, 1, 2, 3, or 4. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4.
[0071] As described above, each R9is independently hydrogen, halogen, -CN, -OR, oxo, -N(R)2, - C(R)2OR, -S(O)2NR2, -C(O)N(R)2, -C(R)2C(O)N(R)2or an optionally substituted group selected from Ci-6 aliphatic, C1-5cycloalkyl, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0072] In some embodiments, R9is hydrogen. In some embodiments, R9is halogen. In some embodiments, R9is -CN. In some embodiments, R9is -OR. In some embodiments, R9is oxo. In some embodiments, R9is -N(R)2. In some embodiments, R9is -C(R)2OR. In some embodiments, R9is -S(O)2NR2. In some embodiments, R9is -C(O)N(R)2. In some embodiments, R9is -C(R)2C(O)N(R)2. In some embodiments, R9is an optionally substituted C1-6aliphatic. In some embodiments, R9is an optionallysubstituted C1-5cycloalkyl. In some embodiments, R9is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1 -4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0073] In some embodiments, each R9is independently halogen, -OR, -N(R)2, optionally substituted Ci-6 aliphatic or optionally substituted C3-6cycloalkyl. In some embodiments, each R9is independently halogen, -OR, -N(R)2, optionally substituted Ci-6 aliphatic or optionally substituted C3-6cycloalkyl.
[0074] In some embodiments, R9is optionally substituted Ci-6 aliphatic. In some embodiments, R9is optionally substituted C3-6cycloalkyl.
[0075] In some embodiments, each R9is independently fluoro, chloro, -OMe, -OEt, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, -CN, or -NIK
[0076] In some embodiments, R9is fluoro. In some embodiments, R9is chloro. In some embodiments, R9is -OMe. In some embodiments, R9is -OEt. In some embodiments, R9is methyl. In some embodiments, R9is difluoromethyl. In some embodiments, R9is trifluoromethyl. In some embodiments, R9is cyclopropyl. In some embodiments, R9is -CN. In some embodiments, R9is -NIK
[0077] In some embodiments, R1together with an optional R9substituent
[0078] In some embodiments, R1together with an optional R9substituent
[0079] In some embodiments, R1together with an optional R9substituent is
[0080] In some embodiments, R9is as depicted in any one of the compounds of Table 1, below.
[0081] In some embodiments, R9is as depicted in any one of the compounds of Table 1A, below.
[0082] In some embodiments, R9is as depicted in any one of the compounds selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350.
[0083] As defined above, Ring B is selected from cubanyl, pyridinone, pyrazolopyridine, indazole, a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instanceswherein Ring B together with substituent R3is selected from
[0084] In some embodiments, Ring B is selected from cubanyl, a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; or wherein Ring Btogether with substituent R3is selected from,
[0085] In some embodiments, Ring B is cubanyl optionally substituted with t instances of R4. In some embodiments, Ring B is a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted with t instances of R4. In some embodiments, Ring B is a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted with t instances of R4. In some embodiments, Ring B is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted with t instances of R4.
[0086] In some embodiments, Ring B is a 6 membered heteroaryl substituted with R3and having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur'. In some embodiments, Ring B is phenyl substituted with one R3. In some embodiments, Ring B is a 5 membered heteroaryl substituted with R3and having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is cyclohexyl substituted with R3and t instances of R4.
[0087] In some embodiments, Ring B is pyridinone, pyrazolopyridine, or indazole, wherein Ring B is optionally substituted with t instances of R4. In some embodiments, Ring B is pyrazolopyridine or indazole, wherein Ring B is optionally substituted with t instances of R4. In some embodiments, Ring B ispyridinone optionally substituted with t instances of R4. In some embodiments, Ring B is pyrazolopyridine optionally substituted with t instances of R4. In some embodiments, Ring B is indazole optionally substituted with t instances of R4. In some embodiments, Ring B is indazole substituted with 1 ethyl group. In some embodiments, Ring B is pyrazolopyridine substituted with 1 ethyl group. In some embodiments, Ring B is pyridinone substituted with 1 trifluoroethyl group. In some embodiments, Ring B is pyridinone substituted with 1 trifluoropropyl group.
[0088] In some embodiments, Ring B is pyridinyl substituted with R3. In some embodiments, Ring B is a pyridazinyl substituted with R3. In some embodiments, Ring B is pyrimidinyl substituted with R3. In some embodiments, Ring B is pyrazinyl substituted with R3. In some embodiments, Ring B is thiophenyl substituted with R3. In some embodiments, Ring B is thiazolyl substituted with R3. In some embodiments, Ring B is tetrahydropyranyl.x1-x2| ( / X^R3
[0089] In some embodiments, Ring B together with substituent R3is selected from x4-x3
[0090] In some embodiments, Ring B together with substituent R3is selected from x4-x3
[0091] In some embodiments, Ring B together with substituent R3is
[0093] In some embodiments, Ring B together with its R3substituent is
[0094] In some embodiments, Ring B together with its R3substituent is
[0095] In some embodiments, Ring B together with its R3substituent is
[0096] In some embodiments, Ring B together with its R3substituent is
[0097] In some embodiments, Ring B together with its R3substituent is, wherein X2is N or CH.
[0098] In some embodiments, Ring B is as depicted in any one of the compounds of Table 1, below.
[0099] In some embodiments, Ring B is as depicted in any one of the compounds of Table 1A, below.
[0100] In some embodiments, Ring B is as depicted in any one of the compounds selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350.
[0101] As described above, t is 0, 1, 2, 3, 4, or 5. In some embodiments, t is 0, 1, 2, 3, or 4. In some embodiments, t is 0. In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t is 3. In some embodiments, t is 4. In some embodiments, t is 5.
[0102] As described above, Z1is CR2or N; Z2is CR2or N; where at least one of Z1or Z2is not N. In some embodiments, Z1is CR2or N and Z2is CR1. In some embodiments, Z1is CR2and Z2is CR1. In some embodiments, Z1is CR2and Z2is N. In some embodiments, Z1is N and Z2is CR1.
[0103] As described above, R2is hydrogen, halogen, -N(R)2, -OR, or optionally substituted C1-6aliphatic. In some embodiments, R2is -N(R)2or -OR. In some embodiments, R2is hydrogen. In some embodiments, R2is halogen. In some embodiments, R2is -N(R)2. In some embodiments, R2is -OR. In some embodiments, R2is optionally substituted C1-6aliphatic.
[0104] As described above, X1, X2, X3and X4are each independently selected from CR4and N. In some embodiments, X1is CR4, X2is CR4, X3is CR4, and X4is CR4. In some embodiments, X1is CR4, X2is CR4, X3is CR4, and X4is N. In some embodiments, X1is CR4, X2is CR4, X3is N, and X4is CR4. In some embodiments, X1is CR4, X2is CR4, X3is N, and X4is N. In some embodiments, X1is CR4, X2is N, X3is CR4, and X4is CR4. In some embodiments, X1is CR4, X2is N, X3is CR4, and X4is N. In some embodiments, X1is CR4, X2is N, X3is N, and X4is CR4. In some embodiments, X1is CR4, X2is N, X3is N, and X4is N. In some embodiments, X1is N, X2is CR4, X3is CR4, and X4is CR4. In some embodiments, X1is N, X2is CR4, X3is CR4, and X4is N. In some embodiments, X1is N, X2is CR4, X3is N, and X4is CR4. In some embodiments, X1is N, X2is CR4, X3is N, and X4is N. In some embodiments, X1is N, X2is N, X3is CR4, and X4is CR4. In some embodiments, X1is N, X2is N, X3is CR4, and X4is N. In some embodiments, X1is N, X2is N, X3is N, and X4is CR4. In some embodiments, X1is N, X2is N, X3is N, and X4is N.
[0105] As described above, X5is CR4, NR, N, O, or S. In some embodiments, X5is CR4. In some embodiments, X5is NR. In some embodiments, X5is N. In some embodiments, X5is O. In some embodiments, X5is S.
[0106] As described above, X6and X7are each independently selected from CR4, NR, N, O, and S.
[0107] In some embodiments, X6is CR4. In some embodiments, X6is NR. In some embodiments, X6is N. In some embodiments, X6is O. In some embodiments, X6is S.
[0108] In some embodiments, X7is CR4. In some embodiments, X7is NR. In some embodiments, X7isN. In some embodiments, X7is O. In some embodiments, X7is S.
[0109] In some embodiments, X6is CR4and X7is CR4. In some embodiments, X6is CR4and X7is NR. In some embodiments, X6is CR4and X7is N. In some embodiments, X6is CR4and X7is O. In some embodiments, X6is CR4and X7is S. In some embodiments, X6is NR and X7is CR4. In some embodiments, X6is NR and X7is NR. In some embodiments, X6is NR and X7is N. In some embodiments, X6is NR and X7is O. In some embodiments, X6is NR and X7is S. In some embodiments, X6is N and X7is CR4. In some embodiments, X6is N and X7is NR. In some embodiments, X6is N and X7is N. In some embodiments, X6is N and X7is O. In some embodiments, X6is N and X7is S. In some embodiments, X6is O and X7is CR4. In some embodiments, X6is O and X7is NR. In some embodiments, X6is O and X7is N. In some embodiments, X6is S and X7is CR4. In some embodiments, X6is S and X7is NR. In some embodiments, X6is S and X7is N.
[0110] In some embodiments, at least one of X5, X6, or X7is N. In some embodiments, at least one of X5, X6, or X7is O. In some embodiments, at least one of X5, X6, or X7is S.
[0111] In some embodiments, X5is S, X6is N, and X7is CR4. In some embodiments, X5is CR4, X6is NR, and X7is N. In some embodiments, X5is CR4, X6is N, and X7is CR4. In some embodiments, X5is N, X6is N, and X7is NR. In some embodiments, X5is CR4, X6is S, and X7is CR4. In some embodiments, X5isO, X6is N, and X7is CR4.
[0112] As described above, X8is C or N. In some embodiments, X8is C. In some embodiments, X8is N.
[0113] As described above, X9is C or N. In some embodiments, X9is C. In some embodiments, X9isN.
[0114] In some embodiments, X8is C and X9is C. In some embodiments, X8is C and X9is N. In some embodiments, X8is N and X9is C. In some embodiments, X8is N and X9is N.
[0115] As described above, R3is an optionally substituted group selected from C3-6aliphatic; C2-6alkoxy; C3-C6cycloalkyloxy; chlorodifluoromethoxy; cycloalkyl substituted methoxy; a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 4-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with s occurrences of R3A.
[0116] In some embodiments, R3is an optionally substituted C3-6 aliphatic. In some embodiments, R3is an optionally substituted C2-6alkoxy. In some embodiments, R3is an optionally substituted C3-C6cycloalkyloxy. In some embodiments, R3is an optionally substituted chlorodifluoromethoxy. In some embodiments, R3is an optionally substituted cycloalkyl substituted methoxy. In some embodiments, R3is an optionally substituted 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R3is an optionally substituted 4-6 membered saturated or partially unsaturatedmonocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R3is substituted with s occurrences of R3A.
[0117] In some embodiments, R3is ethoxy. In some embodiments, R3is trifluoroethoxy. In some embodiments, R3is methyl.N or CH.
[0121] In some embodiments, R3is as depicted in any one of the compounds of Table 1, below.
[0122] In some embodiments, R3is as depicted in any one of the compounds of Table 1A, below.
[0123] In some embodiments, R3is as depicted in any one of the compounds selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350.
[0124] As described above, each R3Ais independently halogen, OR, C3-6cycloalkyl or a mono- or di-C2-6alkyl amino. In some embodiments, R3Ais halogen. In some embodiments, R3Ais OR. In some embodiments, R3AC3-6cycloalkyl. In some embodiments, R3Ais a mono-C2-6alkyl amino. In some embodiments, R3Ais a di-C2-6alkyl amino.
[0125] As described above, s is 0, 1, 2, 3, 4, or 5. In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3. In some embodiments, s is 4. In some embodiments, s is 5.
[0126] As described above, each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic.
[0127] In some embodiments, R4is hydrogen. In some embodiments, R4is -OR. In some embodiments, R4is halogen. In some embodiments, R4is C1-4aliphatic.
[0128] In some embodiments, R3and one occurrence of R4taken together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur.
[0129] In some embodiments, R3and one occurrence of R4are optionally and independently taken together to form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur.
[0130] In some embodiments, R3and one occurrence of R4are taken together to form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R3and one occurrence of R4are taken together to form a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, R3and one occurrence of R4are taken together to form a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur.
[0131] As described above, R5is optionally substituted C1-6aliphatic.
[0132] In some embodiments, R3is hydrogen or optionally substituted C1-6aliphatic. In some embodiments, R5is hydrogen. In some embodiments, R5is unsubstituted C1-6aliphatic. In some embodiments, R3is optionally substituted methyl. In some embodiments, R5is optionally substituted ethyl. In some embodiments, R5is optionally substituted propyl.
[0133] In some embodiments, R5is as depicted in any one of the compounds of Table 1A, below.
[0134] In some embodiments, R6is L-R7; or R3and R6taken in combination form a saturated or partially unsaturated monocyclic heterocycle or saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle each of which is optionally substituted with u occurrences of R8.
[0135] As described above, u is 0, 1, 2, 3, 4, or 5. In some embodiments, u is 0. In some embodiments, u is 1. In some embodiments, u is 2. In some embodiments, u is 3. In some embodiments, u is 4. In some embodiments, u is 5.
[0136] In some embodiments, R6is L-R7.
[0137] As described above, L is a covalent bond or an optionally substituted C1-8 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by -C(R)2-, -Cy-, -N(R)-, -O-, C(O)-, -S-, -S(O)-or -S(O)2-. In some embodiments, L is a covalent bond. In some embodiments, L is an optionally substituted C1-8 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by -C(R)2-, -Cy-, -N(R)-, -O-, C(O)-, -S-, -S(O)- or -S(O)2-. In some embodiments, L is an optionally substituted C1-6 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by -C(R)2-, -Cy- or -N(R)-.
[0138] In some embodiments, L is as depicted in any one of the compounds of Table 1A, below.
[0139] In some embodiments, L is a covalent bond or an optionally substituted C1-8 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by -C(R)2-, -Cy-, -N(R)-, -O-, C(O)-, -S-, -S(O)-or -S(O)2-; each -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0140] In some embodiments, each -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0141] In some embodiments, -Cy- is an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, -Cy- is an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0142] In some embodiments, -Cy- is an optionally substituted 4 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, -Cy- is an optionally substituted 5 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, -Cy- is an optionally substituted 6 membered saturated or partially unsaturated monocyclic carbocyclic ring.
[0143] In some embodiments, -Cy- is an optionally substituted 9 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 9 membered saturated or partially unsaturated spirocyclic ring having 1 nitrogen. In some embodiments, -Cy- is an optionally substituted 9 membered saturated or partially unsaturated spirocyclic ring having 2 nitrogens. In some embodiments, -Cy- is an optionally substituted 9 membered saturated or partially unsaturated spirocyclic ring having 1 nitrogen and 1 oxygen.
[0144] In some embodiments, -Cy- is an optionally substituted 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 7 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 8 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 9 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 7 membered saturated or partially unsaturated bridged bicyclic ring having 1 nitrogen. In some embodiments, -Cy- is an optionally substituted 8 membered saturated or partially unsaturated bridged bicyclic ring having 1 nitrogen. In some embodiments, -Cy- is an optionally substituted 7 membered saturated or partially unsaturated bridged bicyclic ring having 1 nitrogen.
[0145] In some embodiments, -Cy- is an optionally substituted 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 9 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 9 membered saturated or partially unsaturated fused bicyclic ring having 1 nitrogen.
[0146] In some embodiments, -Cy- is cyclobutane. In some embodiments, -Cy- is cyclopentane. In some embodiments, -Cy- is cyclohexane. In some embodiments, -Cy- is piperidine. In some embodiments, -Cy-is tetrahydrofuran. In some embodiments, -Cy- is azetidine.
[0147] In some embodiments, -Cy- is as depicted in any one of the compounds of Table 1A, below.
[0149] In some embodiments, R6is as depicted in any one of the compounds of Table 1A, below.
[0150] In some embodiments, R3and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated monocyclic heterocycle or saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle each of which is optionally substituted with u occurrences of R8.
[0151] As described above, in some embodiments, R5and R6taken together with the nitrogen atom to which they are attached form a 5-7-membered saturated or partially unsaturated monocyclic heterocycle or 8-12-membered saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8.
[0152] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5-7-memebred monocyclic heterocycle or saturated or 8-12-membered partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle optionally substituted with u occurrences of R8.
[0153] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5-7-memebred monocyclic heterocycle or saturated or 8-12-membered partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle optionally substituted with u occurrences of R8, wherein u is 0, 1, or 2.
[0154] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached form a 8- to 12-membered saturated fused bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 0, 1, 2, or 3.
[0155] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 1 or 2
[0156] In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 4-membered monocyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R3and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 5-membered monocyclic heterocycle optionally substituted with u occurrences of Rs. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 6-membered monocyclic heterocycle optionally substituted with u occurrences of R8.
[0157] In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 7-membered fused bicyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R3and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 8-membered fused bicyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 9-membered fused bicyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 10-membered fused bicyclic heterocycle optionally substituted with u occurrences of R8.
[0158] In some embodiments, R3and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 7-membered bridged bicyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 8-membered bridged bicyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 9-membered bridged bicyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 10-membered bridged bicyclic heterocycle optionally substituted with u occurrences of R8.
[0159] In some embodiments, R3and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 7-membered spirocyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 8-membered spirocyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 9-membered spirocyclic heterocycle optionally substituted with u occurrences of R8. In some embodiments, R5and R6, taken in combination with the nitrogen to which they are attached, form a saturated or partially unsaturated 10-membered spirocyclic heterocycle optionally substituted with u occurrences of R8.
[0160] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached39404144454647
[0163] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attachedtaken together with the nitrogen atom to which they are attached form a structure
[0164] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached
[0165] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached
[0166] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attachedform a structure
[0167] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attachedform a structure
[0168] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attachedform a structure
[0169] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached
[0170] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached
[0171] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached
[0172] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached form a structure as depicted in any one of the compounds of Table 1, below.
[0173] In some embodiments, R5and R6taken together with the nitrogen atom to which they are attached form a structure as depicted in any one of the compounds selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350.
[0174] As described above, each R7is independently hydrogen, halogen, -N(R)2, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, -C(R)2OR, -C(R)2C(R)2OR,SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, - N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from Ci-saliphatic, Ci-Cghaloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0175] In some embodiments, R7is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, -C(R)2OR, -C(R)2C(R)2OR,SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2,-N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partiallyunsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0176] In some embodiments, R7is hydrogen, halogen, -N(R)2, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, CN, - OR, -C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, or -N(R)S(O)R.
[0177] In some embodiments, R7is hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, -C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R, -C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2,-N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, or -N(R)S(O)R.
[0178] In some embodiments, R7is an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0179] In some embodiments, R7is as depicted in any one of the compounds of Table 1, below.
[0180] In some embodiments, R7is as depicted in any one of the compounds of Table 1A, below.
[0181] As described above, each R8is hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, -C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R, -C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2,-N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic hctcroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatomsindependently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; ortwo R8together with the atom(s) to which they are attached form a 3-7-membered spiro, fused, or bridged saturated or partially unsaturated monocyclic carbocyclic ring.
[0182] In some embodiments, each R8is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, -C(R)2OR, -C(R)2C(R)2OR,SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2,-N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from Ci-galiphatic, Ci-Cshaloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0183] In some embodiments, R8is hydrogen. In some embodiments, R8is methyl. In some embodiments, R8is fluoro. In some embodiments, R8is chloro. In some embodiments, R8is -NH2. In some embodiments, R8is azetidine.
[0184] In some embodiments, two R8together with the atom(s) to which they are attached form a 3-7-membered spiro, fused, or bridged saturated or partially unsaturated monocyclic carbocyclic ring.
[0185] In some embodiments, R8is as depicted in any one of the compounds of Table 1, below.
[0186] In some embodiments, R8is as depicted in any one of the compounds of Table 1A, below.
[0187] In some embodiments, R8is as depicted in any one of the compounds selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350.55formula I.
[0189] In some embodiments, L is as depicted in any one of the compounds of Table 1A, below.
[0190] As described above, each R is independently hydrogen, -CN, halogen, or an optionally substituted group selected from Cl -6 aliphatic; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ringhaving 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur” a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or: two R groups on the same carbon or nitrogen are taken together to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0191] In some embodiments, two R groups on the same carbon or nitrogen are taken together to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0192] In some embodiments, R is as depicted in any one of the compounds of Table 1, below.
[0193] In some embodiments, R is as depicted in any one of the compounds of Table 1A, below.
[0194] In some embodiments, R is as depicted in any one of the compounds selected from 1-151, 1-165, 1- 282, 1-283, 1-293, 1-309, and 1-350.
[0195] In some embodiments, the present disclosure provides a compound represented by any one of the following formulae:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described herein both individually and in combination.
[0196] In some embodiments, the present disclosure provides a compound represented by any one of the following formulae:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described herein both individually and in combination.
[0197] In some embodiments, the present disclosure provides a compound represented by any one of the following formulae:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described herein both individually and in combination.
[0198] In some embodiments, the present disclosure provides a compound represented by any one of the following formulae:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described herein both individually and in combination.
[0199] In some embodiments, a compound of Formula I has a structure of Formula II:wherein R1is phenyl, isoxazolyl, or pyrazolyl, R1is optionally substituted with q instances of R9; q is 0, 1 or 2; Ring B is phenyl, pyridyl, or cyclohexyl, and is substituted with R3and with t instances of R4; t is 0, 1 or 2; Z1is CH or N; R’ and R6taken together with the nitrogen atom to which they are attached form a 5- to 7 -membered saturated or partially unsaturated monocyclic heterocycle or 8- to 12-membered saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 0, 1, 2, 3, or 4.
[0200] In some embodiments of compounds of Formula (II) or sub-formulae thereof, Z1is CH or N. In some embodiments of compounds of Formula (II) or sub-formulae thereof, Z1is CH. In some embodiments of compounds of Formula (II) or sub-formulae thereof, Z1is N.
[0201] In some embodiments of compounds of Formula (II) or sub-formulae thereof, Ring B is phenyl, pyridyl, or cyclohexyl. In some embodiments of compounds of Formula (II) or sub-formulae thereof, Ring B is phenyl or pyridyl. In some embodiments of compounds of Formula (II) or sub-formulae thereof, Ring B is cyclohexyl.
[0202] In some embodiments of compounds of Formula (II) or sub-formulae thereof, Ring B and any
[0203] In some embodiments of compounds of Formula (II) or sub-formulae thereof, t is 0. In some embodiments of compounds of Formula (II) or sub-formulae thereof, t is 1. In some cases, R3is C2-ealkoxy optionally substituted with s occurrences of R3A. In some cases, R3is C2-ealkoxy substituted with s occurrences of R3A. In some cases, R3is substituted with s R3A, s being 0, 1, 2, or 3. In some cases, R3is substituted with s R3A, s being 0. In some cases, R3is substituted with s R3A, s being 3. In some cases, R3is unsubstituted C2-ealkoxy. In some cases, R3Ais halogen. In some cases, R3Ais fluoro. In some cases, R3is trifluoroethoxy. In some cases, R3is ethoxy.
[0204] In some embodiments of compounds of Formula (II) or sub-formulae thereof, Ring B and any
[0205] In some embodiments of compounds of Formula (II) or sub-formulae thereof, Ring B and anysubstituents have a structure, wherein X2is N or CH.
[0206] In some embodiments of compounds of Formula (II) or sub-formulae thereof, Ring B and anysubstituents have a structure ofwherein X2is N or CH.
[0207] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R5and R6taken in combination form a saturated or partially unsaturated monocyclic heterocycle or saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle each of which is optionally substituted with u occurrences of R8, and u is 0, 1, 2, 3, or 4. In some embodiments of compounds of Formula (II) or subformulae thereof, R5and R6taken in combination form a saturated fused bicyclic heterocycle substituted with u occurrences of R8, and u is 0, 1, 2, 3, or 4. In some embodiments of compounds of Formula (II) orsub-formulae thereof, R5and R6taken in combination form a saturated monocyclic heterocycle substituted with u occurrences of R8, and u is 1 or 2.R6-^(R8)UI 'V-N.
[0208] In some embodiments of Formula (II) or sub-formulae thereof, has a structure ofR6-'^I '(R8)U
[0209] In some embodiments of Formula (II) or sub-formulae thereof,has a structure ofR6-(R8)UI;Y D5
[0211] In some embodiments of Formula (II) or sub-formulae thereof, has a structure ofR6Z(R8)UI / VN.
[0212] In some embodiments of Formula (II) or sub-formulae thereof, R5has a structure ofR6-(R8)UI
[0213] In some embodiments of Formula (II) or sub-formulae thereof,has a structure of
[0214] In some embodiments of Formula (II) or sub-formulae thereof,has a structure ofR6-(R8)U
[0215] In some embodiments of Formula (II) or sub-formulae thereof,has a structure of
[0216] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is hydrogen. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is optionally substituted Ci-galiphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is unsubstituted Ci-saliphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is unsubstituted Ci-2aliphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, Rsis methyl. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is N(R)2. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is N(R), wherein both R are hydrogen. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is N(R)2, wherein one R is hydrogen and the other R is optionally substituted Ci-6 aliphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, Rsis N(R)2, wherein one R ishydrogen and the other R is unsubstituted Ci-6 aliphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R8is N(R)2, wherein one R is hydrogen and the other R is methyl.R6- ^(R8)UI '
[0217] In some embodiments of Formula (II) or sub-formulae thereof,has a structure ofR6- (R8)UY R*
[0218] In some embodiments of Formula (II) or sub-formulae thereof, has a structure ofR6-^(R8)UI 'Y R5
[0219] In some embodiments of Formula (II) or sub-formulae thereof, has a structure ofR6-(R8)UI
[0220] In some embodiments of Formula (II) or sub-formulae thereof,has a structure ofR6-'^I '(R8)u
[0221] In some embodiments of Formula (II) or sub-formulae thereof,has a structure ofR I 6 Z(R8)UN.
[0222] In some embodiments of Formula (II) or sub-formulae thereof, has a structure ofR6-(R8)UI
[0223] In some embodiments of Formula (II) or sub-formulae thereof,has a structure of
[0224] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R1is phenyl, isoxazolyl, or pyrazolyl, R1is optionally substituted with q instances of R9, and q is 0, 1 or 2. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R1is phenyl. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R1is isoxazolyl or pyrazolyl.
[0225] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R1and any
[0226] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R9is optionally substituted Ci-6 aliphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R9is halogen. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R9isunsubstituted Ci-6 aliphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R9is unsubstituted C1-3aliphatic. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R9is absent, methyl or fluoro. In some embodiments of compounds of Formula (II) or subformulae thereof, R9is methyl. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R9is fluoro. In some embodiments of compounds of Formula (II) or sub-formulae thereof, R9is absent.
[0227] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R1and anysubstituents have a structure of In some embodiments,
[0228] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R1has a structure
[0229] In some embodiments of compounds of Formula (II) or sub-formulae thereof, R1and anysubstituents have a structure of In some embodiments, R1is
[0230] In some cases, a compound of the disclosure has a structure of Formula Ila:wherein R1is phenyl or pyrazolyl substituted with 0 or1 R9;R5and R6taken together with the nitrogen atom to which they are attached form a 8- to 12-membered saturated fused bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 0, 1, 2, or
[0231] In some cases, a compound of the disclosure has a structure of Formula lib:(lib), wherein X2is N or CH; R1is isoxazolyl or pyrazolyl substituted with 1 R9;R5and R6taken together with the nitrogen atom to which they are attached form a 5- to7-membered saturated monocyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, andu is 1 or 2.
[0232] In some cases, a compound of the disclosure has a structure of Formula lie:wherein Ring B is pyridyl or phenyl; R1is pyrazolyl or isoxazolyl substitutedcompound of the disclosure has a structure of Formula lid:), wherein Ring B is cyclohexyl; R1is phenyl or pyrazolyl substituted with 0 or 1 R9; and u is 1, 2, or 3.EMBODIMENTS OF THE DISCLOSURE
[0234] Exemplary compounds of the disclosure are set forth in Table 1, and Table 1A or a pharmaceutically acceptable salt thereof. Table 1 and Table 1A identifies compounds by their IUPAC name and shows their chemical structure. The chemical names in the present application are generated fromthe corresponding structures using either CHEMDRAW, or CHEMAXON. In some instances, chemical names generated from the structures may give a different structure when using the “Convert Name to Structure” function in CHEMDRAW. In the event of any discrepancy between Table 1’s and Table lA’s name for a compound and structure for that same compound, structure will dominate and identify the compound corresponding to each respective compound number (I-#) in Table 1 and Table 1A.Table 1. Selected CompoundsTable 1A. Selected Compounds155
[0235] In some embodiments, the present disclosure provides a compound set forth in Table 1, above, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound set forth in Table 1, above.
[0236] In some embodiments, the present disclosure provides a compound set forth in Table 1A, above, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound set forth in Table 1A, above.
[0237] In some embodiments, the present disclosure provides a compound selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and I-350.
[0238] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound disclosed herein (described in embodiments herein, both singly and in combination), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, excipient, or diluent. For example, in some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula I as defined above, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, excipient, or diluent. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula I as defined above, together with a pharmaceutically acceptable carrier, excipient, or diluent. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound set forth in Table 1 above, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, excipient, or diluent.Embodiments1. A compound of formula I:Ior a pharmaceutically acceptable salt thereof, wherein:R1is halogen, alkoxy, C3-7cycloalkoxy, haloalkoxy, a C3-7cycloalkyl, phenyl, cubanyl, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a C5-12 bridged bicyclic carbocyclic ring, or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein each R1is optionally substituted with q instances of R9;q is 0, 1, 2, 3, or 4;each R9is independently hydrogen, halogen, -CN, -OR, oxo, -N(R)2, - C(R)2OR, -S(O)2NR2, -C(O)N(R)2, -C(R)2C(O)N(R)2or an optionally substituted group selected from C1-6 aliphatic, C1-5cycloalkyl, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Z1is CR2or N; Z2is CR2or N; where at least one of Z1or Z2is not N;R2is hydrogen, halogen, -N(R)2, -OR, or optionally substituted Ci-6aliphatic;Ring B is selected from cubanyl, pyridinone, pyrazolopyridine, indazole, a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orwherein Ring B together with substituent R3is selected from; wherein:X1, X2, X3, and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;Xsis C or N;X9is C or N;R3is an optionally substituted group selected from C3-6aliphatic; C2-6alkoxy; C3-C6cycloalkyloxy; chlorodifluoromethoxy; cycloalkyl substituted methoxy; a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 4-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with s occurrences of R3A;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4taken together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur;each R3Ais independently halogen, OR, C3-6cycloalkyl or a mono- or di-C2-6alkyl amino;s is 0, 1, 2, 3, 4, or 5t is 0, 1, 2, 3, or 4;R5is optionally substituted C1-6aliphatic;R6is L-R7; orR5and R6taken together with the nitrogen atom to which they are attached form a 5-7-membered saturated or partially unsaturated monocyclic heterocycle or 8-12-membered saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8;L is a covalent bond or an optionally substituted C1-8bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by –C(R)2-, -Cy-, –N(R)-, -O-, C(O)-, -S-, -S(O)- or –S(O)2-;each -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered satur ated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each R7is independently hydrogen, halogen, -N(R)2, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R8is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R, -C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 memberedsaturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; ortwo R8together with the atom(s) to which they are attached form a 3-7-membered spiro, fused, or bridged saturated or partially unsaturated monocyclic carbocyclic ring;u is 0, 1, 2, 3, 4, or 5;each R is independently hydrogen, -CN, halogen, or an optionally substituted group selected from Ci-6 aliphatic; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- 10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; ortwo R groups on the same carbon or nitrogen are taken together to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.2. The compound of embodiment 1, wherein:Ring B is selected from a 6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orRing B together with substituent R3iswherein:X1, X2, X3, and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4taken together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; andt is 0, 1, 2, 3, or 4.3. The compound of embodiment 1 or 2, wherein:Ring B together with substituent R3iswherein:at least one of X3, X6, or X7is N; orat least one of X3, X6, or X7is O; orat least one of X5, X6, or X7is S; orX5is S, X6is N, and X7is CR4; orX5is CR4, X6is NR, and X7is N; orX5is CR4, X6is N, and X7is CR4; orX5is NR, X6is N, and X7is NR; orX5is CR4, X6is S, and X7is CR4; orX5is O, X6is N, and X7is CR4.4. The compound of any one of embodiments 1-3, wherein Ring B together with substituent R3is selected5. The compound of any one of embodiments 1-4, wherein R1is selected from:7. The compound of any one of embodiments 1-6, wherein q is 1.8. The compound of any one of embodiments 1-6, wherein q is 0.9. The compound of any one of embodiments 1-7, wherein each R9is independently halogen, -OR, - N(R)2, optionally substituted C1-6aliphatic or optionally substituted Cs-ecycloalkyl.10. The compound of any one of embodiments 1-7, wherein each R9is independently fluoro, chloro, -OMe, -OEt, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, -CN or -NH2.11. The compound of any one of embodiments 1-5, wherein12. The compound of any one of embodiments 1-5 or 11, wherein R9is optionally substituted C1-6aliphatic or optionally substituted C3-6cycloalkyl.13. The compound of any one of embodiments 1-12, wherein Z1is CR1and Z2is CR2or N.14. The compound of any one of embodiments 1-12, wherein Z1is CR2or N and Z2is CR1.15. The compound of any one of embodiments 1-14, wherein R5and R6taken together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5-7-memebred monocyclic heterocycle or saturated or 8-12-membered partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle optionally substituted with u occurrences of R8.16. The compound of embodiment 15, wherein u is 0, 1, or 2.17. The compound of embodiment 15 or 16, wherein the group -N(R5)(R6) is selected from18. The compound of embodiment 17, wherein the group -N(R5)(R6) is selected from:19. The compound of embodiment 19, wherein the group -N(R5)(R6) is selected from:20. The compound of any one of embodiments 1-19, wherein R2is hydrogen.21. The compound of any one of embodiments 1-19, wherein R2is halogen, optionally substituted C1-6aliphatic, -N(R)2or -OR.22. The compound of any one of embodiments 1-21 wherein the compound is selected from any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.23. The compound of any one of embodiments 1-21 of any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.24. The compound of any one of embodiments 1-21 of any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.25. The compound of any one of embodiment 1-21 of any one of the following formulae:or a pharmaceutically acceptable salt thereof.26. The compound of any one of embodiments 1-25, having a structure of:whereinR1is phenyl, isoxazolyl, or pyrazolyl, R1is optionally substituted with q instances of R9;q is 0, 1 or 2;Ring B is phenyl, pyridyl, or cyclohexyl, and is substituted with R3and with t instances of R4;t is 0, 1 or 2;Z1is CH or N;R5and R6taken together with the nitrogen atom to which they are attached form a 5- to 7-memebred saturated or partially unsaturated monocyclic heterocycle or 8- to 12-membered saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, andu is 0, 1, 2, 3, or 4.27. The compound of embodiments 26, wherein Ring B and any substituents have a structure of28. The compound of embodiment 27, wherein Ring B and any substituents have a structure ofR6-^(R8)UI;VN. *29. The compound of any one of embodiment 26 to 28, wherein * has a structure ofHN—The compound of embodiment 29, whereinhas a structure of31. The compound of any one of embodiments 26 to 30, wherein R1has a structure of33. The compound of embodiment 26, having a structure of:R1is phenyl or pyrazolyl substituted with 0 or1 R9;R5and R6taken together with the nitrogen atom to which they are attached form a 8- to 12-membered satur ated fused bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 0, 1, 2, or 3.34. The compound of embodiment 26, having a structure of:X2is N or CH;R1is isoxazolyl or pyrazolyl substituted with 1 R9;R5and R6taken together with the nitrogen atom to which they are attached form a 5- to7-membered satur ated monocyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 1 or 2.35. The compound of embodiment 26, having a structure of:whereinRing B is pyridyl or phenyl:R1is pyrazolyl or isoxazolyl substituted with 1 R9, andu is 1 or 2.36. The compound of embodiment 26, having a structure of:whereinRing B is cyclohexyl;R1is phenyl or pyrazolyl substituted with 0 or 1 R9; andu is 1, 2, or 3.37. The compound of any one of embodiments 26 to 36, wherein R9is absent, methyl or fluoro.38. The compound of any one of embodiments 26 to 37, wherein R3is ethoxy.39. The compound of any one of embodiments 26 to 38, wherein at least one R8is methyl.40. The compound of any one of embodiments 26 to 39, wherein at least one R8is N(R)2and at least oneR is H.41. The compound of any one of the embodiments 1-40, wherein the compound is selected from those depicted in Table 1, or a pharmaceutically acceptable salt thereof.42. The compound selected from those depicted in Table Al, or a pharmaceutically acceptable salt thereof.43. The compound of embodiment 41, wherein the compound is selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350 or a pharmaceutically acceptable salt thereof.44. A pharmaceutical composition comprising a compound according to any one of embodiments 1-43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.45. The compound of any one of embodiments 1-43, or the pharmaceutical composition of embodiment 44, for use as a medicament.46. A method of inhibiting SLC in a biological sample, comprising contacting the sample with the compound of any one of embodiments 1-43, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of embodiment 44.47. A method of treating an SLC-mediated disorder, disease, or condition in a patient, comprising administering to said patient the compound of any one of embodiments 1-43, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of embodiment 44.48. The method of embodiment 47, wherein the SLC-mediated disorder, disease, or condition is an autoimmune disorder, disease, or condition.49. The method of embodiment 47, wherein the SLC-mediated disorder, disease, or condition is an inflammatory disorder, disease, or condition.50. The method of embodiment 48 or 49, wherein the SLC-mediated disorder, disease, or condition is selected from Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, Graves' Disease, Hashimoto's thyroiditis, myasthenia gravis, type 1 diabetes mellitus, Multiple Sclerosis (MS), pemphigus vulgaris, Antiphospholipid Syndrome (APS), granulomatosis with polyangiitis (Wegener's Granulomatosis), eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome), dermatomyositis, polymyositis, systemic sclerosis (scleroderma), ankylosing spondylitis, ulcerative colitis, crohn's disease, celiac disease, vitiligo atopic dermatitis, psoriasis, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, lupus nephritis, pernicious anemia, sclerosing cholangitis, infectious mononucleosis, B-cell lymphomas, chronic fatigue syndrome / myalgic encephalomyelitis, Aicardi-Goutières Syndrome (AGS), spondyloenchondrodysplasia with immune dysregulation, STING-Associated Vasculopathy with Onset in Infancy (SAVI), Japanese Autoinflammatory Syndrome with Lipodystrophy (JASL), Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature (CANDLE), ubiquitin-specific peptidase 18 (USP18) deficiency, PNPT1-associated mitochondrial disease, SAMHD1-associated interferonopathy, ADAR1-associated interferonopathy, systemic lupus erythematosis, lupus nephritis, cutaneous lupus, Cryopyrin- Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis, metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma-related bone disorder, acutemyelogenous leukemia, chronic myelogenous leukemia, autoimmune pancreatitis (AIP), type I diabetes mellitus, antiphospholipid syndrome (APS), sclerosing cholangitis, systemic onset arthritis, irritable bowel disease (IBD), pemphigus vulgaris, pemphigus foliaceus, autoimmune hepatitis, hypopituitarism, graft-versus-host disease (GvIID), autoimmune skin diseases, uveitis, pernicious anemia, and hypoparathyroidism, polyangiitis overlap syndrome, Kawasaki's disease, sarcoidosis, lomerulonephritis, cryopathies, Cutaneous Lupus (CLE), hidradenitis suppurativa, Blau syndrome, lung fibrosis, asthma, graft versus host disease, allograft rejection, inflammatory bowel disease, psoriasiform dermatitis, endosomal TLR-dependent inflammation, endosomal TLR-induced hyperinflammation, macrophage activation syndrome, allergic airway inflammation, sarcoidosis, sepsis, septic shock, Shigellosis, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HIV infection and CMV retinitis, AIDS, hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), ARC or malignancy, herpes, Waldenstrom’s Macroglobulinemia (WM), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), cutaneous diffuse large B cell lymphoma, and primary CNS lymphoma, Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury, pancreatitis (acute or chronic), allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, chronic thyroiditis, autoimmune gastritis, diabetes, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic β-cell disease, diseases characterized by massive neutrophil infiltration, rheumatoid spondylitis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, keloid formation, scar tissue formation, pyresis, influenza, angiogenic disorders including solid tumors, ocular neovasculization, infantile haemangiomas, stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hypoxia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia, toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris.Further Embodiments1A. A compound of formula I:Ior a pharmaceutically acceptable salt thereof, wherein:R1is halogen, alkoxy, haloalkoxy, a C3-7 cycloalkyl, phenyl, cubanyl, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a C5-12 bridged bicyclic carbocyclic ring, or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein each R1is optionally substituted with q instances of R9;q is 0, 1, 2, 3, or 4;each R9is independently hydrogen, halogen, -CN, -OR, oxo, -N(R)2, - C(R)2OR, -S(O)2NR2, -C(O)N(R)2, -C(R)2C(O)N(R)2or an optionally substituted group selected from C1-6 aliphatic, C1-5cycloalkyl, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Z1is CR2or N; Z2is CR2or N; where at least one of Z1or Z2is not N;R2is hydrogen, halogen, -N(R)2, -OR, or optionally substituted C1-6aliphatic;Ring B is selected from cubanyl, a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orx1-x2j —-R3wherein Ring B together with substituent R3is selected from x4=x3; wherein:X1, X2, X3and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;Xsis C or N;X9is C or N;R3is an optionally substituted group selected from C3-6aliphatic; C2-6alkoxy; C3-C6cycloalkyloxy; chlorodifluoromethoxy; cycloalkyl substituted methoxy; a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 4-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with s occurrences of R3A;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4are optionally and independently taken together to form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered hctcroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur;each R3Ais independently halogen, OR, C3-6cycloalkyl or a mono- or di-C2-6alkyl amino;s is O, 1, 2, 3, 4 or 5t is 0, 1, 2, 3, or 4;R5is hydrogen or optionally substituted C1-6aliphatic;R6is L-R7; orR5and R6taken in combination form a saturated or partially unsaturated monocyclic heterocycle or saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle each of which is optionally substituted with u occurrences of R8;L is a covalent bond or an optionally substituted C1-8bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by -C(R)2-, -Cy-, -N(R)-, -O-, C(O)-, -S-, -S(O)- or -S(O)2-;each -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R7is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R8is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic hctcroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ringhaving 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;u is O, 1, 2, 3, 4 or 5;each R is independently hydrogen, -CN, halogen, or an optionally substituted group selected from Ci-6 aliphatic; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- 10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:two R groups on the same carbon or nitrogen are taken together to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.2A. The compound of embodiment 1A, wherein:Ring B is selected from a 6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orRing B together with substituent R3iswherein:X1, X2, X3and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4are optionally and independently taken together to form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; andt is 0, 1, 2, 3, or 4.3 A. The compound of embodiment 1 A or 2A, wherein:Ring B together with substituent R3iswherein:at least one of X3, X6, or X7is N; orat least one of X5, X6, or X7is O; orat least one of X5, X6, or X7is S; orX5is S, X6is N, and X7is CR4; orX5is CR4, X6is NR, and X7is N; orX5is CR4, X6is N, and X7is CR4; orX5is NR, X6is N, and X7is NR; orX5is CR4, X6is S, and X7is CR4; orX5is O, X6is N, and X7is CR4.4A. The compound of any one of embodiments 1A-3A, wherein Ring B together with substituent R3is5A. The compound of any one of embodiments 1A-4A, wherein R1is selected from:6A. The compound of any one of embodiments 1A-5A, wherein R1is7A. The compound of any one of embodiments 1A-6A, wherein q is 1.8A. The compound of any one of embodiment 1A-6A, wherein q is 0.9A. The compound of any one of embodiments 1 A-7A, wherein each R9is independently halogen, -OR, -N(R)2, optionally substituted Ci-6 aliphatic or optionally substituted C3-6cycloalkyl.10A. The compound of any one of embodiments 1A-7A, wherein each R9is independently fluoro, chloro, -OMe, -OEt, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, -CN or -NH2.11 A. The compound of any one of embodiments 1 A-5A, wherein12A. The compound of any one of embodiments 1 A-5A or 11 A, wherein R9is optionally substituted C1-6aliphatic or optionally substituted C3-6cycloalkyl.13 A. The compound of any one of embodiments 1A-12A, wherein Z1is CR1and Z2is CR2or N.14A. The compound of any one of embodiments 1A-12A, wherein Z1is CR2or N and Z2is CR1.15A. The compound of any one of embodiments 1A-14A, wherein L is a covalent bond.16A. The compound of any one of embodiments 1A-14A, wherein L is an optionally substituted Ci-6 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by –C(R)2-, -Cy- or –N(R)-; andeach -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0- 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.17A. The compound of any one of embodiments 1A-14A or 16A, wherein L is selected fromwherein * denotes the point of attachment to the amide nitrogen.18A. The compound of any one of embodiments 1A-17A, wherein R5is hydrogen.19A. The compound of any one of embodiments 1A-17A, wherein u is 0, 1, or 2.20A. The compound of any one of embodiments 1A-19A, wherein each R7is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, -C(R)2OR, - SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, -C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2,-N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, or -N(R)S(O)R.21A. The compound of any one of embodiments 1A-19A, wherein each R7is an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.23 A. The compound of any one of embodiments 1A-22A, wherein the group -N(R5)(R6) is selected from19224A. The compound of any one of embodiments 1A-23A, wherein the group -N(R5)(R6) is selected from:25A. The compound of any one of embodiments 1A-24A, wherein R2is hydrogen.26A. The compound of any one of embodiments 1A-24A, wherein R2is halogen.27A. The compound of any one of embodiments 1 A-24A, wherein R2is -N(R)2or -OR.28A. The compound of any one of embodiments 1A-24A, wherein R2is optionally substituted C1-6aliphatic.29A. The compound of any one of embodiments 1A-28A wherein the compound is selected from any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.30A. The compound of any one of embodiments 1A-28A of any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.31 A. The compound of any one of embodiments 1A-28A of any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.32A. The compound of any one of embodiments 1A-28A of any one of the following formulae:or a pharmaceutically acceptable salt thereof.33A. The compound of any one of the embodiments 1A-32A, wherein the compound is selected from those depicted in Table 1, or a pharmaceutically acceptable salt thereof.34A. A pharmaceutical composition comprising a compound according to any one of embodiments 1 A-33A, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.35A. The compound of any one of embodiments 1A-33A, or the pharmaceutical composition of embodiment 34A, for use as a medicament.36A. A method of inhibiting SLC in a biological sample, comprising contacting the sample with the compound of any one of embodiments1A-33A, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of embodiment 34A.37A. A method of treating an SLC-mediated disorder, disease, or condition in a patient, comprising administering to said patient the compound of any one of embodiments 1A-33A, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of embodiment 34A.38A. The method of embodiment 37A, wherein the SLC-mediated disorder, disease, or condition is an autoimmune disorder, disease, or condition.39A. The method of embodiment 37A, wherein the SLC-mediated disorder, disease, or condition is an inflammatory disorder, disease, or condition.40A. The method of embodiment 38A or 39A, wherein the SLC-mediated disorder, disease, or condition is selected from Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, Graves' Disease, Hashimoto's thyroiditis, myasthenia gravis, type 1 diabetes mellitus, Multiple Sclerosis (MS), pemphigus vulgaris, Antiphospholipid Syndrome (APS), granulomatosis with polyangiitis (Wegener's Granulomatosis), eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome), dermatomyositis, polymyositis, systemic sclerosis (scleroderma), ankylosing spondylitis, ulcerative colitis, crohn's disease, celiac disease, vitiligo atopic dermatitis, psoriasis, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, lupus nephritis, pernicious anemia, sclerosing cholangitis, infectious mononucleosis, B-cell lymphomas, chronic fatigue syndrome / myalgic encephalomyelitis, Aicardi-Goutières Syndrome (AGS), spondyloenchondrodysplasia with immune dysregulation, STING-Associated Vasculopathy with Onset in Infancy (SAVI), Japanese Autoinflammatory Syndrome with Lipodystrophy (JASL), Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature (CANDLE), ubiquitin-specific peptidase 18 (USP18) deficiency, PNPT1-associated mitochondrial disease, SAMHD1-associated interferonopathy, ADAR1-associated interferonopathy, systemic lupus erythematosis, lupus nephritis, cutaneous lupus, Cryopyrin- Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis, metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, autoimmune pancreatitis (AIP), type I diabetes mellitus, antiphospholipid syndrome (APS), sclerosing cholangitis, systemic onset arthritis, irritable bowel disease (IBD), pemphigus vulgaris, pemphigus foliaceus, autoimmune hepatitis, hypopituitarism, graft-versus-host disease (GvHD), autoimmune skin diseases, uveitis, pernicious anemia, and hypoparathyroidism, polyangiitis overlap syndrome, Kawasaki's disease, sarcoidosis, lomerulonephritis, cryopathies, Cutaneous Lupus (CLE), hidradenitis suppurativa, Blau syndrome, lung fibrosis, asthma, graft versus host disease, allograft rejection, inflammatory bowel disease, psoriasiform dermatitis, endosomal TLR-dependent inflammation, endosomal TLR-induced hyperinflammation, macrophage activation syndrome, allergic airway inflammation, sarcoidosis, sepsis, septic shock, Shigellosis, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HIV infection and CMV retinitis, AIDS, hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), ARC or malignancy, herpes, Waldenstrom’s Macroglobulinemia (WM), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), cutaneous diffuse large B cell lymphoma, and primary CNS lymphoma, Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury, pancreatitis (acute orchronic), allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, chronic thyroiditis, autoimmune gastritis, diabetes, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic β-cell disease, diseases characterized by massive neutrophil infiltration, rheumatoid spondylitis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, keloid formation, scar tissue formation, pyresis, influenza, angiogenic disorders including solid tumors, ocular neovasculization, infantile haemangiomas, stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hypoxia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia, toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris.4. General Methods of Providing the Present Compounds
[0239] The compounds of this disclosure may be prepared or isolated in general by synthetic and / or semisynthetic methods known to those skilled in the art for analogous compounds and by methods described in detail in the Examples, herein.
[0240] In certain embodiments, compounds of the present disclosure are generally prepared according to any one of the schemes set forth below:
[0241] Compounds of the present disclosure (e.g., Formula I), in general, may be prepared (e.g., according to General Scheme 1 below) by making Intermediates 1 via C-C coupling reactions (Suzuki, Stille, or the like), or C-N or C-0 coupling reactions (Ullmann, Buchwald, SNAr, or others), to first obtain (B) from commercial building blocks (A). Another C-C, C-N, or C-0 coupling reaction can furnish (C), and subsequent saponification leads to Intermediate 1 (General Scheme 1). Intermediates 1 are then converted to the corresponding amides (I) using substituted primary or secondary amines and amide coupling reagents and conditions known in the art. Where applicable, target compounds (e.g., compounds of Formula I) are obtained after separation by chiral HPLC and / or deprotection. Those having ordinary skill in the art will be able to attach R1, R2, and R3in different sequence orders, using similar reactions and protection / deprotection methods known in the art (see, e.g., General Scheme 2). One skilled in the art would also recognize that the use of “amine” in an amide coupling reaction could refer to a primary or secondary amine, affording the corresponding amide.General Scheme 11. NH(R5)(R6)amide coupling reagent2. chiral separation & saponification deprotection if applicable - ► step 3 step 4Intermediate 1General Scheme 2catalystbasesolvent saponificationstep 1 - step 2 ►1. R1B(OR)2or R1SnR3or heterocycle / amineor alcohol5. Uses, Formulation and Administration, Pharmaceutically acceptable compositions
[0242] According to another embodiment, the disclosure provides a composition comprising a compound of this disclosure or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In certain embodiments, the amount of compound in compositions of thisdisclosure is such that is effective to measurably inhibit SLC, or a mutant thereof, in a biological sample or in a patient. In certain embodiments, a composition of this disclosure is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this disclosure is formulated for oral administration to a patient.
[0243] The term “patient,” as used herein, means an animal, preferably a mammal, and most preferably a human.
[0244] The term “pharmaceutically acceptable earner, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose -based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylenepolyoxypropylene -block polymers, polyethylene glycol and wool fat.
[0245] A “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this disclosure that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this disclosure or an inhibitory active metabolite or residue thereof.
[0246] As used herein, the term "active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of SLC, or a mutant thereof.
[0247] The subject matter disclosed herein includes prodrugs, metabolites, derivatives, and pharmaceutically acceptable salts of compounds of the disclosure. Metabolites include compounds produced by a process comprising contacting a compound of the disclosure with a mammal for a period of time sufficient to yield a metabolic product thereof. If the compound of the disclosure is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the ait, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitic acid, methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like. If the compound of the disclosure is an acid, the desired pharmaceuticallyacceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
[0248] A compound of the disclosure can be in the form of a "prodrug," which includes compounds with moieties which can be metabolized in vivo. Generally, the prodrugs are metabolized in vivo by esterases or by other mechanisms to active drugs. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) " Pharmaceutical Salts", J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Prodrugs which are converted to active forms through other mechanisms in vivo are also included. In aspects, the compounds of the disclosure are prodrugs of any of the formulae herein.
[0249] Compositions of the present disclosure may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this disclosure may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
[0250] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[0251] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0252] In order to prolong the effect of a compound of the present disclosure, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-poly glycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[0253] Alternatively, pharmaceutically acceptable compositions of this disclosure may be administered in the form of suppositories for rectal or vaginal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
[0254] Pharmaceutically acceptable compositions of this disclosure may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
[0255] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
[0256] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Gamers for topical administration of compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0257] Dosage forms for topical or transdermal administration of a compound of this disclosure include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this disclosure. Additionally, the present disclosure contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0258] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, in some embodiments, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
[0259] Pharmaceutically acceptable compositions of this disclosure may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.
[0260] In some embodiments, pharmaceutically acceptable compositions of this disclosure are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this disclosure are administered without food.In other embodiments, pharmaceutically acceptable compositions of this disclosure are administered with food.
[0261] Pharmaceutically acceptable compositions of this disclosure may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
[0262] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0263] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0264] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known inthe pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0265] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0266] The compounds of this disclosure, or pharmaceutical compositions thereof, may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However, patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with a compound of this disclosure are another embodiment of the present disclosure.
[0267] The amount of compounds of the present disclosure that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. In some embodiments, provided compositions should be formulated so that a dosage of between 0.01 and 100 mg / kg, 0.01 and 50 mg / kg, or 1 and 25 mg / kg, body weight / day of the compound can be administered to a patient receiving these compositions.
[0268] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount ofa compound of the present disclosure in the composition will also depend upon the particular compound in the composition.
[0269] In some embodiments, compounds of the disclosure are formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment.4. Uses of Compounds and Pharmaceutically Acceptable Compositions
[0270] Compounds and compositions described herein are generally useful for the inhibition SLC family proteins. In some embodiments the SLC inhibited by the compounds and methods of the disclosure is SLC 15 A3 or SLC15A4.
[0271] The presently disclosed compounds find use in inhibiting SLC. In one embodiment, the subject matter disclosed herein is directed to a method of inhibiting SLC, the method comprising contacting SLC with an effective amount of a compound of the disclosure or a pharmaceutical composition described herein.
[0272] The presently disclosed compounds can be used in a method for inhibiting SLC. Such methods comprise contacting SLC with an effective amount of a presently disclosed compound. By "contact" is intended bringing the compound within close enough proximity to an isolated SLC or a cell expressing SLC such that the compound is able to bind to and inhibit the SLC. The compound can be contacted with SLC in vitro or in vivo via administration of the compound to a subject.
[0273] In one aspect, provided herein is a method of inhibiting SLC in a biological sample. The method comprises contacting the sample with a compound disclosed herein (such as a compound of Formula I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein (such as a composition comprising a compound disclosed herein (such as a compound of Formula I) and a pharmaceutically acceptable earner, adjuvant, or vehicle). The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[0274] Any method known in the art to measure the activity of SLC may be used to determine if SLC has been inhibited, including in vitro assays, immunoblots with antibodies specific for phosphorylated targets of SLC, or the measurement of a downstream biological effect of SLC activity.
[0275] Provided herein are compounds and pharmaceutical compositions that inhibit SLC, as well as methods of treatment using such compounds and pharmaceutical compositions. The compounds andcompositions can be used in methods of modulating the immune system, for treatment of diseases, and for treatment of cells in vivo, in vitro, or ex vivo.
[0276] The present disclosure provides methods of inhibiting SLC in a patient. The method comprises administering to a patient a compound disclosed herein (such as a compound of Formula I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein (such as a composition comprising a compound disclosed herein (such as a compound of Formula I) and a pharmaceutically acceptable carrier, adjuvant, or vehicle).
[0277] The presently disclosed compounds can be used to treat a SLC-mediated disorder. As used herein, a " SLC-mediated disorder" is a pathological condition in which SLC activity is necessary for the genesis or maintenance of the pathological condition.
[0278] Accordingly, in one aspect, provided herein is a method of treating a SLC-mediated disorder, disease, or condition in a patient. The method comprises administering to said patient a compound disclosed herein (such as a compound of Formula I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein (such as a composition comprising a compound disclosed herein (such as a compound of Formula I) and a pharmaceutically acceptable carrier, adjuvant, or vehicle).
[0279] In some embodiments, the SLC-mediated disorder is selected from autoimmune diseases or disorders, inflammatory diseases or disorders, oncologic and infectious diseases or disorders, and neurodegenerative disorders.
[0280] Accordingly, there is a body of evidence based on genetic studies of systemic lupus erythematosus (SLE) in human cells indicating the role SLC15A4 in this disorder. Bentham et al. (PMID: 26502338) identified through GWAS the genetic association of SLC15A4 and TASL (referenced therein as CXorf21) with SLE in a cohort of European ancestry. Han and coworkers (PMID: 19838193) identified through GWAS the genetic association of SLC15A4 with SLE in a cohort of a Chinese Han population. He CF and coworkers (PMID: 20516000) identified through GWAS the genetic association of SLCL5A4 with SLE-related discoid rash in a Chinese Han population. Langefeld and coworkers (PMID: 28714469) identified through GWAS the genetic association of SLC15A4 with SLE in a cohort of European ancestry.
[0281] Further, there is a body of evidence based on genetic studies of systemic lupus erythematosus (SLE) in human cells indicating the role TASL in this disorder. Bentham et al. (PMID: 26502338) identified through GWAS the genetic association of SLC15A4 and TASL (referenced therein as CXorf21) with SLE in a cohort of European ancestry. Odhams et al. (PMID: 31092820) proposed that genetic variants of TASL (CXorf21) associated with SLE lead to increased TASL expression in an interferon- and sex-specific manner and hence suggest a potential explanation.
[0282] There is further a body of evidence in mouse models indicating the importance of TASL / SLC15A4 in systemic lupus erythematosus. Baccala and coworkers (PMID: 23382217) identified a protective role forSLC15A4 deficiency in the development of SLE in a mouse model using the C57BL / 6-Fas(lpr) strain. Kobayashi and coworkers (PMID: 25238095) show that SLC15A4-deficiency is protective in two models of SLE (pristane-induced and C57BL / 6Ipr / Ipr mice) and that SLC15A4 is required in B cells for endosomal TLR function. Pollard and coworkers (PMID: 29055005) find that SLC15A4-deficiency is protective in a mercury-induced model of SLE. Katewa and coworkers (PMID: 33444326) describe a protective role for SLC15A4 in pristane-induced and NZB / WF1 murine genetic models of SLE.Accordingly, compounds of the present disclosure are considered useful in the treatment or prevention of autoimmune diseases or disorders, inflammatory diseases or disorders, oncologic and infectious diseases or disorders, and neurodegenerative disorders.
[0283] In some embodiments, the autoimmune disease or disorder, inflammatory disease or disorder, oncologic and infectious disease or disorder, and neurodegenerative disease or disorder is selected from: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, Graves' Disease, Hashimoto's thyroiditis, myasthenia gravis, type 1 diabetes mellitus, Multiple Sclerosis (MS), pemphigus vulgaris, Antiphospholipid Syndrome (APS), granulomatosis with polyangiitis (Wegener's Granulomatosis), eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome), dermatomyositis, polymyositis, systemic sclerosis (scleroderma), ankylosing spondylitis, ulcerative colitis, crohn's disease, celiac disease, vitiligo atopic dermatitis, psoriasis, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, lupus nephritis, pernicious anemia, sclerosing cholangitis, infectious mononucleosis, B-cell lymphomas, chronic fatigue syndrome / myalgic encephalomyelitis, Aicardi-Goutières Syndrome (AGS), spondyloenchondrodysplasia with immune dysregulation, STING-Associated Vasculopathy with Onset in Infancy (SAVI), Japanese Autoinflammatory Syndrome with Lipodystrophy (JASL), Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature (CANDLE), ubiquitin-specific peptidase 18 (USP18) deficiency, PNPT1-associated mitochondrial disease, SAMHD1-associated interferonopathy, ADAR1-associated interferonopathy, rheumatoid arthritis, systemic lupus erythematosis, lupus nephritis, cutaneous lupus, psoriasis; Cryopyrin-Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis; metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma-related bone disorder; proliferative disorders such as acute myelogenous leukemia, chronic myelogenous leukemia, rheumatoid arthritis (RA), autoimmune pancreatitis (AIP), systemic lupus erythematosus (SLE), type I diabetes mellitus, multiple sclerosis (MS), antiphospholipid syndrome (APS), sclerosing cholangitis, systemic onset arthritis, irritable bowel disease (IBD), scleroderma, Sjogren's disease, vitiligo, polymyositis, pemphigus vulgaris, pemphigus foliaceus, inflammatory bowel disease including Crohn'sdisease and ulcerative colitis, autoimmune hepatitis, hypopituitarism, graft-versus-host disease (GvHD), autoimmune skin diseases, uveitis, pernicious anemia, and hypoparathyroidism. Autoimmune diseases may also include, without limitation, polyangiitis overlap syndrome, Kawasaki's disease, sarcoidosis, lomerulonephritis, and cryopathies.
[0284] In some embodiments, the autoimmune disease or disorder, inflammatory disease or disorder, oncologic and infectious disease or disorder, and neurodegenerative disease or disorder is selected from: Inflammatory bowel diseases, Cutaneous Lupus (CLE), vitiligo, hidradenitis suppurativa, Blau syndrome, lung fibrosis, atherosclerosis, Crohn's disease, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic, obstructive pulmonary disease, inflammatory bowel disease, psoriasiform dermatitis, endosomal TLR-dependent inflammation, ulcerative colitis, Crohn’s disease, endosomal TLR-induced hyperinflammation, macrophage activation syndrome, allergic airway inflammation, and sarcoidosis, sepsis, septic shock, and Shigellosis, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HIV infection and CMV retinitis, AIDS, hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), ARC or malignancy, herpes, Waldenstrom’s Macroglobulinemia (WM), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), cutaneous diffuse large B cell lymphoma, and primary CNS lymphoma, Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury, pancreatitis (acute or chronic), asthma, allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic 3-cell disease; diseases characterized by massive neutrophil infiltration; rheumatoid spondylitis, gouty arthritis and other arthritic conditions, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, keloid formation, scar- tissue formation, ulcerative colitis, pyresis, influenza, osteoporosis, osteoarthritis, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, sepsis, septic shock, and Shigellosis; Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury; angiogenic disorders including solid tumors, ocular neovasculization, and infantile haemangiomas; stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hypoxia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiachypertrophy, thrombin-induced platelet aggregation, endotoxemia and / or toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris.
[0285] In some embodiments, the present disclosure provides a method of treating transplantation rejection diseases involving impairment of cartilage turnover in a patient in need thereof, wherein the method comprises administering to the patient a compound disclosed herein (such as a compound of Formula I) or a pharmaceutically acceptable salt thereof.
[0286] In some embodiments, the present disclosure provides a method of treating inflammatory bowel disease in a patient in need thereof, wherein the method comprises administering to the patient a compound disclosed herein (such as a compound of Formula I) or a pharmaceutically acceptable salt thereof.
[0287] In some embodiments, the present disclosure provides a method of treating a skin pigmentation disease in a patient in need thereof, wherein the method comprises administering to the patient a compound disclosed herein (such as a compound of Formula I) or a pharmaceutically acceptable salt thereof.
[0288] In some embodiments, the present disclosure provides a method of treating osteoporosis in a patient in need thereof, wherein the method comprises administering to the patient a compound disclosed herein (such as a compound of Formula I) or a pharmaceutically acceptable salt thereof.
[0289] In some embodiments, the present disclosure provides a method of treating arthritis in a patient in need thereof, wherein the method comprises administering to the patient a compound disclosed herein (such as a compound of Formula 1) or a pharmaceutically acceptable salt thereof.
[0290] In some embodiments, the present disclosure provides a method of treating a musculoskeletal disease in a patient in need thereof, wherein the method comprises administering to the patient a compound disclosed herein (such as a compound of Formula I) or a pharmaceutically acceptable salt thereof.
[0291] In some embodiments, the present disclosure provides a method of treating rheumatoid arthritis in a patient in need thereof, wherein the method comprises administering to the patient a compound disclosed herein (such as a compound of Formula I) or a pharmaceutically acceptable salt thereof.
[0292] There is a body of evidence based on genetic studies indicating the role of SLC15A4 and / or TASL in inflammatory conditions. Heinz and coworkers (PMID: 32433612) have shown essential role of SLC15A4-TASL and their relationship in human cell lines and primary cells for endosomal TLR function.
[0293] There is a body of evidence based on the studies in mouse models indicating the role of SLC15A4 and / or TASL in inflammatory conditions. Blasius and coworkers (PMID: 21045126) identified SLC15A4 as essential component in endosomal TLR function in plasmacytoid dendritic cells. Sasawatari and coworkers (PMID: 21277849) have found SLC15A4-deficiency to impair CpG-induced production of inflammatory cytokines from dendritic cells. Furthermore, SLC15A4-deficiency was found to be protective in a mouse model of inflammatory bowel disease. SLC15A4-deficient mice also showed defective cytokine production upon activation of the NOD-like receptor NODI. Blasius and coworkers (PMID: 23028315)suggested an important role for SLC 15 A4 in pDCs in controlling viral persistence, as evidenced in a model of LCMV infection. Nakamura and coworkers (PMID: 24695226) proposed a role for SLC15A4 in the activation of NOD2 at the lysosome. Of note, NOD2 mutations are linked to inflammatory bowel disease. Dosenovic and coworkers (PMID: 25310967) find defective endosomal TLR function in pDCs, splenic eDCs and B cells. Furthermore, production of antibodies elicited by a CpGA-adjuvanted vaccine is impaired in SLC15A4 mice. Griffith and coworkers (PMID: 30262916) describe a requirement for SLC15A4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice. Lopez-Haber and coworkers (PMID: 36031853) describe a contribution of SLC15A4 in inflammasome activation via mTORCl signaling pathways.
[0294] In some embodiments, compounds of the present disclosure are useful in the treatment of prevention of inflammatory condition, preferably selected from inflammatory bowel disease, psoriasiform dermatitis, endosomal TLR-dependent inflammation, ulcerative colitis, Crohn’s disease, endosomal TLR-induced hyperinflammation, macrophage activation syndrome, allergic airway inflammation, and sarcoidosis, preferably wherein the inflammatory condition is selected from inflammatory bowel disease, psoriasiform dermatitis, and endosomal TLR-dependent inflammation.
[0295] Accordingly, in some embodiments, compounds of the present disclosure are useful in treatment or prevention of an inflammatory condition.
[0296] In some embodiments, the present disclosure relates to a compound of Formula 1, or pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, for use in the treatment or prevention of an autoimmune disorder or an inflammatory condition. In some embodiments, the present disclosure relates to a compound of Formula I or pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, for use in the treatment or prevention of an autoimmune disorder. In some embodiments, the present disclosure relates to a compound of Formula I, or pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, for use in the treatment or prevention of an inflammatory condition.
[0297] In some embodiments, the inflammatory condition is selected from inflammatory bowel disease, psoriasiform dermatitis, endosomal TLR-dependent inflammation, ulcerative colitis, Crohn’s disease, endosomal TLR-induced hyperinflammation, macrophage activation syndrome, allergic airway inflammation, and sarcoidosis. In certain embodiments, the inflammatory condition is selected from inflammatory bowel disease, psoriasiform dermatitis, and endosomal TLR-dependent inflammation.
[0298] In some embodiments, the present disclosure relates to use of a compound of Formula I or pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, in the manufacture of a medicament for use in the treatment or prevention of an autoimmune disorder or an inflammatory condition. In some embodiments, the present disclosure relates to use of a compound of Formula I or pharmaceuticallyacceptable salt thereof, or pharmaceutical composition thereof, in the manufacture of a medicament for use in the treatment or prevention of an autoimmune disorder. In some embodiments, the present disclosure relates to use of a compound of Formula I or pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, in the manufacture of a medicament for use in the treatment or prevention of an inflammatory condition.
[0299] In some embodiments, the present disclosure relates to a method of treating an autoimmune disorder, the method comprising administering a compound of Formula I, or pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, to a subject in need thereof. It is to be understood that said compound or its salt or said pharmaceutical composition is to be administered in a therapeutically effective amount, as described herein.
[0300] In some embodiments, the present disclosure relates to a compound of Formula I, or pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, for use in the treatment or prevention of an autoimmune disorder, wherein the autoimmune disorder is selected from systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, polymyositis / dermatomyositis, primary biliary cirrhosis, multiple sclerosis, oral ulcers, periodontitis, Behcet’s disease, myasthenia gravis, and ankylosing spondylitis. In certain embodiments, the autoimmune disorder is systemic lupus erythematosus.
[0301] In some embodiments, compounds of the present disclosure are also useful in treatment or prevention of other lupus diseases such as cutaneous or neonatal lupus erythematosus.
[0302] It is understood that appropriate doses of the active compound depend upon a number of factors. The dose(s) of the active compound will vary, for example, depending upon the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, and any drug combination.
[0303] It will also be appreciated that the effective dosage of a compound of the disclosure or a pharmaceutically acceptable salt, prodrug, metabolite, or derivative thereof used for treatment may increase or decrease over the course of a particular treatment.
[0304] In some embodiments, an SLC inhibitor or compound of formula I, or pharmaceutically acceptable salt thereof, is administered to the subject at a dose of between about 0.001 mg / kg and about 1000 mg / kg, including but not limited to about 0.001 mg / kg, 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 10 mg / kg, 25 mg / kg, 50 mg / kg, 100 mg / kg, 250 mg / kg, 500 mg / kg, 1 mg / kg, 5 mg / kg, 10 mg / kg, 25 mg / kg, 50 mg / kg, 100 mg / kg, and 200 mg / kg.
[0305] In some embodiments, the SLC inhibitor is administered to the subject at a dose of between about 0.1 mg and about 10 g, including but not limited to about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 500 mg, 750 mg, 1 g, 2 g, 5 g, and 10 g.
[0306] As used herein, the terms “treatment,” “treat,” and “heating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment is administered after one or more symptoms have developed. In other embodiments, treatment is administered in the absence of symptoms. For example, in some embodiments, treatment is administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). In some embodiments, treatment is continued after symptoms have resolved, for example to prevent or delay their recurrence.
[0307] In some embodiments, compounds of the present disclosure are useful in preventing or reducing the risk of developing any of the diseases referred to herein; e.g., preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
[0308] The term "administration" or "administering" includes routes of introducing the compound(s) to a subject to perform their intended function. Examples of routes of administration which can be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), topical, oral, inhalation, rectal and transdermal.
[0309] The term "effective amount" includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result. An effective amount of compound may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response.
[0310] The phrases "systemic administration," "administered systemically", "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes.
[0311] The phrase "therapeutically effective amount" means an amount of a compound of the present disclosure that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.5. Combination Therapies
[0312] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents, which are normally administered to treat that condition, may be administered in combination with compounds and compositions of this disclosure. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as “appropriate for the disease,or condition, being treated.” In certain embodiments, a provided combination, or composition thereof, is administered in combination with another therapeutic agent.
[0313] Those additional agents may be administered separately from a provided combination therapy, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this disclosure in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another.
[0314] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this disclosure. For example, a combination of the present disclosure may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
[0315] The amount of additional therapeutic agent present in the compositions of this disclosure will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. In some embodiments, the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[0316] In one embodiment, the present disclosure provides a composition comprising a compound of Formula 1 and one or more additional therapeutic agents. The therapeutic agent may be administered together with a compound of Formula I, or may be administered prior to or following administration of a compound of Formula I. In certain embodiments, a compound of Formula I may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours before the therapeutic agent. In other embodiments, a compound of Formula I may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours following the therapeutic agent.EXEMPLIFICATION
[0317] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present disclosure, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein. Additional compounds of the disclosure wereprepared by methods substantially similar to those described herein in the Examples and methods known to one skilled in the art.
[0318] AbbreviationsH2O: water Min: minutesPd(PPh3)4: tetrakis(triphenylphosphine) eq: equivalencePalladium Pd(dppf)Cl2:K2CO3: potassium carbonate bis(diphenylphosphino)ferrocene]dichloropalladACN: acetonitrile ium(II), complexHC1: hydrochloride acid Na2CO3: sodium carbonateaq.: aqueous LiOH: lithium hydroxideFA: formic acid THF: tetrahydrofuranNa2SO4: sodium sulfate PE: petroleum etherEtOAc: ethyl acetate Prep-TLC: preparative thin layerNH4HCO3: ammonium bicarbonate chromatographyDCM: dichloromethane Boc: tert-butyloxy carbonylDEA: diethylamine Hex: hexaneEtOH: ethanol Pd(dppf)2Cl2-CH2Cl2:1,1'- MeOH: methanol bis(diphenylphosphino)ferrocene- N2: nitrogen palladium(II )dichloride dichloromethaneDMSO-rk: deuterated dimethyl sulfoxide complexNH3: ammonia TFA: trifluoroacetic acidTCFH: chloro-N,N,NN', N'- DMSO: dimethyl sulfoxide tetramethylformamidinium-hexafluorophosphate CsF: cesium fluorideNMI: 1 -methyl- IH-imidazole DME: dimethyl etherTMSOTf: trimethylsilyl CS2CO3: cesium carbonate trifluoromethanesulfonate Cu2O: cuprous oxideLCMS: liquid chromatography-mass RuPhos: 2-dicyclohexylphosphino-2',6'-spectrometry diisopropoxybiphenylHPLC: high-performance liquid chromatography RuPhos-Pd-G3: (2-dicyclohexylphosphino-2',6'- 5: chemical shift diisopropoxy- 1, 1 '-biphenyl) [2-(2'-amino- 1,1'-h / hr: hour biphenyl)]palladium(II)methansulfonat1H NMR: proton nuclear magnetic resonance NaOH: sodium hydroxideGeneral Synthetic Methods
[0319] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present disclosure were either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21). Further, the compounds of the present disclosure can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples.
[0320] Proton NMR (1H NMR) was conducted in deuterated solvent. In certain compounds disclosed herein, one or more1H shifts overlap with residual proteo solvent signals; these signals have not been reported in the experimental provided hereinafter.
[0321] LCMS was conducted using the following methods:Example 1. Synthesis of Intermediate 1-1Step 1. Synthesis of methyl 6-bromo-[2,2'-bipyridine]-4-carboxylate
[0322] A mixture of methyl 2,6-dibromoisonicotinate (24.0 g, 81.4 mmol, 1.0 eq), 2-(tributylstannyl)pyridine (30.0 g, 81.4 mmol, 1.0 eq) and Pd(PPh3)4 (9.40 g, 8.14 mmol, 0.1 eq) in 1,4-dioxane (240 mL) was stirred at 100°C for 16 h under N2 atmosphere. The mixture was allowed to cool down to room temperature and was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of EtOAc / PE) to afford the title compound. LCMS: 293[M+H]+.Step 2. Synthesis of methyl 6-(4-(2,2,2-trifluoroethoxy)phenyl)-[2,2'-bipyridine]-4-carboxylate
[0323] A mixture of methyl 6-bromo-[2,2'-bipyridine]-4-carboxylate (5.0 g, 17.1 mmol, 1.0 eq), (4-(2,2,2-trifluoroethoxy)phenyl)boronic acid (3.75 g, 17.1 mmol, 1.0 eq), Na2CO3 (5.42 g, 51.3 mmol, 3.0 eq) and Pd(dppf)C12 (1.25 g, 1.71 mmol, 0.1 eq) in 1,4-dioxane (50 mL) and H2O (5 mL) was stirred at 80°C for 2 h under N2 atmosphere. The mixture was allowed to cool down to room temperature. The precipitated solids were removed by filtration and washed with EtOAc. The filtrate was diluted with H2O (100 mL) and then extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of EtOAc / PE) to afford the title compound. LCMS: 389[M+H]+. ’H NMR (400 MHz, DMSO-rfc) 5 8.76 - 8.73 (m, 1H), 8.73 - 8.71 (m, 1H), 8.60 - 8.55 (m, 1H), 8.32 - 8.24 (m, 3H), 8.05 - 7.99 (m, 1H), 7.56 - 7.50 (m, 1H), 7.27 - 7.21 (m, 2H), 4.93 - 4.85 (m, 2H), 3.97 (s, 3H).Step 3. Synthesis of 6-(4-(2,2,2-trifluoroethoxy)phenyl)-[2,2'-bipyridine]-4-carboxylic acid
[0324] To a stirred mixture of methyl 6-(4-(2,2,2-trifluoroethoxy)phenyl)-[2,2'-bipyridine]-4-carboxylate (2.20 g, 5.67 mmol, 1.0 eq) in THF (10 mL) was added a solution of LiOH (274 mg, 11.3 mmol, 2.0 eq) in H2O (10 mL) at room temperature. The mixture was stirred for 1 h at room temperature and then acidified to pH 5 with IM HC1 (aq.). The solution was diluted with H2O (100 mL) and then was extracted with EtOAc (3 x 120 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was used in the next step without further purification. LCMS: 375[M+H]+. ‘H NMR (400 MHz, DMSO-rfc) 8 8.76 - 8.73 (m, 2H), 8.62 - 8.57 (m, 1H), 8.33 - 8.30 (m, 1H), 8.29 - 8.24 (m, 2H), 8.05 - 8.00 (m, 1H), 7.54 - 7.48 (m, 1H), 7.26 - 7.21 (m, 2H), 4.92 - 4.84 (m, 2H).Example 2: Synthesis of Intermediate 1-2Intermediate 1-2Step 1. Synthesis of 2-chloro-6-(l-methyl-lH-pyrazol-4-yl)isonicotinic acid
[0325] To a stirred solution of 2,6-dichloropyridine-4-carboxylic acid (20.0 g, 105 mmol, 1.0 eq) and 1-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole (21.8g, 105 mmol, 1.0 eq) in 1,4-dioxane (200 mL) and H2O (20 mL) were added K2CO3 (43.5 g, 315 mmol, 3.0 eq) and Pd(dppf)Cl2·CH2Cl2 (8.57 g, 10.5 mmol, 0.1 eq) at room temperature under N2. The resulting mixture was stirred at 100°C for 1 h under N2. The resulting mixture was allowed to cool down to room temperature, filtered, the filter cake was washed with H2O (20 mL). The filtrate was concentrated under reduced pressure. The residue was diluted with H2O and then was extracted with EtOAc to remove some impurity. The aqueous layer was acidified to pH 3 with IN HC1 (aq.). The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound, which was used in the next step directly without further purification. LCMS: 238[M+H]+.Step 2. Synthesis of 2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2 trifluoroethoxy)phenyl)-isonicotinic acid
[0326] To a stirred solution of 2-chloro-6-(l -methyl- lH-pyrazol-4-yl)isonicotinic acid ( 10.0 g, 42.1 mmol, 1.0 eq) and 4-(2,2,2-trifluoroethoxy)phenylboronic acid (11.1 g, 50.5 mmol, 1.2 eq) in 1,4-dioxane (100 mL) and H2O (10 mL) were added K2CO3 (17.4 g, 126 mmol, 3.0 eq) and Pd(PPh3)4 (4.86 g, 4.21 mmol, 0.1 eq) at room temperature under N2. The resulting mixture was stirred at 80°C for 2 h under N2. The resulting mixture was allowed to cool down to room temperature, filtered and the filter cake was washed with H2O (20 mL). The filtrate was concentrated under reduced pressure. The residue was dissolved in H2O (50 mL), and then was extracted with EtOAc to remove impurities. The aqueous phase was acidified to pH 3 with IN HC1 (aq.). The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated underreduced pressure. The residue was purified by reverse phase HPLC (C18 column, water (0.05% TFA)-ACN) to afford the title compound. LCMS: 378[M+H]+.Example 3: Synthesis of Intermediate 1-3Intermediate 1-3Step 1. Synthesis of methyl 2-chloro-3-fluoro-6-(l-methyl-lH-pyrazol-4-yl)isonicotinate
[0327] To a mixture of (1 -methyl- lH-pyrazol-4-yl)boronic acid (449 mg, 3.57 mmol, 1.0 eq), methyl 2,6-dichloro-3-fluoroisonicotinate (800 mg, 3.57 mmol, 1.0 eq) in dioxane (10 mL) and H2O (2 mL) were added Pd(PPh3)4 (300 mg, 0.26 mmol, 0.07 eq) and K2CO3 (1.48 g, 10.7 mmol, 3.0 eq) at room temperature. The mixture was degassed three times with N2 and stirred for 1 h at 90°C under N2 atmosphere. The mixture was allowed to cool down to room temperature, diluted with H2O (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of EtOAc / PE) to afford the title compound. LCMS: 270 [M+HJ+.Step 2. Synthesis of methyl 2-(4-ethoxyphenyl)-3-fluoro-6-(l-methyl-lH-pyrazol-4-yl)isonicotinate
[0328] To a mixture of methyl 2-chloro-3-fluoro-6-(l-methyLlH-pyrazol-4-yl)isonicotinate (300 mg, 1.11 mmol, 1.0 eq) and (4-ethoxyphenyl)boronic acid (184 mg, 1.11 mmol, 1.0 eq) in dioxane (4 mL) and H2O (0.5 mL) were added Pd(dppf)Cl2·CH2Cl2 (70 mg, 85.7 pmol, 0.08 eq) and K2CO3 (461 mg, 3.34 mmol, 3.0 eq) at room temperature. The mixture was degassed three times with N2 and stirred for 4 h at 90°C under N2 atmosphere. The mixture was allowed to cool down to room temperature, diluted with H2O (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue waspurified by flash silica gel chromatography (eluent of EtOAc / PE) to afford the title compound. LCMS: 356 [M+H]+.Step 3. Synthesis of 6-(4-ethoxyphenyl)-3-fluoro-2-(l-methyl-lH-pyrazol-4-yl)isonicotinic acid
[0329] To a solution of methyl 2-(4-ethoxyphenyl)-3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)isonicotinate (200 mg, 561 pmol, 1.0 eq) in MeOH (2 mL) was added a solution of NaOH (90 mg, 2.25 mmol, 4.0 eq) in H2O (2 mL) at room temperature. The resulting mixture was stirred for 4 h at 60°C. The mixture was allowed to cool down to room temperature and concentrated under reduced pressure. The residue was dissolved in ACN and purified by reverse phase HPLC (Cl 8 column, water (0.1% FA)-ACN) to afford the title compound. LCMS: 342 [M+H]+.Example 4: Synthesis of Intermediate 1-4Intermediate 1-4Step 1. Synthesis of 2-chloro-6-(4-ethoxyphenyl)pyrimidine-4-carboxylic acid
[0330] To a stirred solution of methyl 2,6-dichloropyrimidine-4-carboxylate (10.0 g, 48.3 mmol, 1.0 eq) and (4-ethoxyphenyl)boronic acid (8.02 g, 48.3 mmol, 1.0 eq) in dioxane (100 mL) and H2O (12.5 mL) were added K2CO3 (13.3 g, 96.6 mmol, 2.0 eq) and Pd(PPh3)4 (5.58 g, 4.83 mmol, 0.1 eq) at room temperature. The resulting mixture was degassed three times with N2 and then stirred at 90°C for 2 h under N2 atmosphere. The resulting mixture was filtered, and the filter cake was washed with EtOAc. The l iltrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of DCM / MeOH) to afford the title compound. LCMS: 279[M+H]+.Step 2. Synthesis of 6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carboxylic acid
[0331] To a stirred mixture of 2-chloro-6-(4-ethoxyphenyl)pyrimidine-4-carboxylic acid (4.10 g, 14.7 mmol, 1.0 eq) and (1 -methyl- lH-pyrazol-4-yl)boronic acid (1.85 g, 14.7 mmol, 1.0 eq) in dioxane (40 mL) and H2O (4 mL) were added K2CO3 (4.07 g, 29.4 mmol, 2.0 eq) and Pd(dppf)Cl2·CH2Cl2 (1.20 g, 1.47 mmol, 0.1 equiv) at room temperature. The mixture was degassed three times with N2 and then stirred at 80°C for overnight under N2 atmosphere. The resulting mixture was filtered, and the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (C18 column, water (0.1% TFA)-ACN) to afford the title compound. LCMS: 325[M+H]+.Example 5: Synthesis of Intermediate 2-1Boc BocBocstereoisomer 1 stereoisomer 2Step 1. Separation of tert-butyl octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (single stereoisomer, first eluting compound as stereoisomer 1) and tert-butyl octahydro-4H-pyrrolo[3,2-b] pyridine- 4-carboxy late (single stereoisomer, second eluting compound as stereoisomer 2)
[0332] Tert-butyl octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (racemic mixture, cis) was separated by chiral HPLC to afford the title compounds. Detailed information of chiral HPLC / SFC: Preparative method column: JW-CHIRALPAK IG-3, 3 x 25 cm, 5 um; mobile phase A: EtOH: DCM=1:1, mobile phase B: Hex (0.5% 2M NH₃-MeOH); flow rate: 45 mL / min; isocratic 85% B; wavelength: 220 nm; sample solvent: EtOH: DCM=1:1; retention time: RT1: 8.32 min (stereoisomer 1); RT2: 11.02 min (stereoisomer 2).
[0333] Analytical method: Instrument LC-93; column: CHIRALPAK IH-3, 3.0 x 50 mm, 3 pm; mobile phase A: CO2; mobile phase B: MeOH (0.5% 2M NH₃-MeOH); isocratic 60 % B; flow: 2 mL / min; temperature: 35°C; UV: 210 nm; retention time: RT1: 0.656 min (stereoisomer 1); RT2: 1.062 min (stereoisomer 2).
[0334] After chiral resolution: Tert-butyl octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (single stereoisomer, first eluting stereoisomer as stereoisomer 1) LCMS: 227 [M+H]+. 1H NMR (400 MHz, DMSO-rfc) 54.32 - 4.20 (m, 1H), 3.74 - 3.71 (m, 1H), 2.92 - 2.64 (m, 5H), 1.80 - 1.75 (m, 1H), 1.67 -1.50 (m, 3H), 1.40 (s, 9H), 1.26 - 1.19 (m, 2H).
[0335] Tert-butyl octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (single stereoisomer, second eluting stereoisomer as stereoisomer 2) LCMS: 227 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 4.25 - 4.22 (m, 1H), 3.75 -3.72 (m, 1H), 3.17 -2.9 (m, 1H), 2.93 - 2.79 (m, 3H), 2.70 - 2.64 (m, 1H), 1.82- 1.74 (m, 1H), 1.67 - 1.50 (m, 3H), 1.40 (s, 9H), 1.26 - 1.19 (m, 2H).Step 2. Synthesis of 2-chloro-6-(4-(2,2,2-trifluoroethoxy)phenyl)pyrimidine-4-carboxylic acid
[0336] A mixture of methyl 2,6-dichloropyrimidine-4-carboxylate (3.0 g, 14.5 mmol, 1.0 eq), (4-(2,2,2-trifluoroethoxy)phenyl)boronic acid (2.23 g, 10.1 mmol, 0.7 eq), K2CO3 (4.01 g, 29 mmol, 2.0 eq) and Pd(PPh3)4 (1.67 g, 1.45 mmol, 0.1 eq) in 1,4-dioxane (30 mL) and H2O (3 mL) was degassed three times with N2, and then was stirred for 2 h at 80“C. The mixture was allowed to cool down to room temperature, diluted with H2O (50 mL), and then was extracted with EtOAc (3 x 50 mL) to remove impurities. The aqueous layer was acidified to pH 6 with IN HC1 (aq.). The precipitated solids were collected by filtration, washed with EtOAc, and dried under reduced pressure to afford the title compound, which was used in the next step directly without further purification. LCMS: 333[M+H]+.Step 3. Synthesis of cis-tert-butyl l-(2-chloro-6-(4-(2,2,2-trifluoroethoxy)phenyl)pyrimidine-4-carbonyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate
[0337] To a stirred mixture of 2-chloro-6-(4-(2,2,2-trifluoroethoxy)phenyl)pyrimidine-4-carboxylic acid (300 mg, 902 pmol, 1.0 eq) and cis-tert-butyl octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (204 mg, 902 pmol, 1.0 eq) in ACN (3 mL) were added NMI (222 mg, 2.70 mmol, 3.0 eq) and TCFH (506 mg, 1.80 mmol, 2.0 eq) at room temperature. After stirring for 30 min at room temperature, the mixture was diluted with H2O (10 mL), and then was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound, which was used in the next step directly without further purification. LCMS: 541[M+H]+.Example 6: Synthesis of Intermediate 2-2Step 1. Synthesis of 2,6-dichloro-N-(3-(piperidin-l-yl)propyl)isonicotinamide
[0338] To a stirred solution of 2,6-dichloroisonicotinic acid (2.40 g, 12.5 mmol, 1.0 eq) and 3-(piperidin-l-yl)propan-l -amine (2.13 g, 15.0 mmol, 1.2 eq) in ACN (20 mL) were added NMI (3.08 g, 37.5 mmol, 3.0 eq) and TCFH (7.01 g, 25.0 mmol, 2.0 eq) at room temperature. The mixture was stirred at room temperature for 2 h. After completion of the reaction, the reaction was quenched by the addition of H2O (60 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 40 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (eluent of EtOAc / PE) to afford the title compound. LCMS: 316 [M+H]+.Step 2. Synthesis of 2-chloro-6-(4-ethoxyphenyl)-N-(3-(piperidin-l-yl)propyl)isonicotinamide
[0339] To a solution of 2,6-dichloro-N-(3-(piperidin-l-yl)propyl)isonicotinamide (40 mg, 0.12 mmol, 1.0 eq) and (4-ethoxyphenyl)boronic acid (25 mg, 0.15 mmol, 1.25 eq) in DME (1 mL) were added CsF (38 mg, 0.25 mmol, 2.08 eq) and Pd(dppf)CL (9 mg, 0.01 mmol, 0.08 eq) at room temperature under N2 atmosphere. The resulting mixture was stirred at 80°C for 16 h. The resulting mixture was cooled down to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (Cl 8 column, water (10 mmol NH4HCO3)-ACN to afford the title compound. LCMS: 402 [M+H]+.Example 7: Synthesis of Intermediate 2-3Step 1. Synthesis of 2-chloro-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinic acid
[0340] To a stirred solution of 2,6-dichloroisonicotinic acid (10.0 g, 52.1 mmol, 1.0 eq) and (4-(2,2,2-trifluoroethoxy)phenyl)boronic acid (10.3 g, 46.9 mmol, 0.9 eq) in 1,4-dioxane (100 mL) and H2O (10 mL) were added K2CO3 (14.4 g, 104 mmol, 2.0 eq) and Pd(dppf)C12 (4.25 g, 5.21 mmol, 0.1 eq). The resulting mixture was degassed three times with N2 and then stirred for 1 h at 90°C under N2 atmosphere. The resulting mixture was cooled down to room temperature, diluted with H2O (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organic layers were washed with brine, dried over anhydrousand filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of EtOAc / MeOH) to afford the title compound. LCMS: 332 [M+H]+.Step 2. Synthesis of tert-butyl 4-(2-chloro-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinamido)piperidine-l-carboxylate
[0341] To a stirred mixture of 2-chloro-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinic acid (2 g, 6.03 mmol, 1.0 eq) and tert-butyl 4-aminopiperidine- 1 -carboxylate (1.21 g, 6.03 mmol, 1.0 eq) in ACN (20 mL) were added TCFH (3.38 g, 12.1 mmol, 2.0 eq) and NMI (1.98 g, 24.1 mmol, 4.0 eq). The resulting mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (Cl 8 column, water (0.1% TFA)-ACN) to afford the title compound. LCMS: 514 [M+II]+.Example 8: Synthesis of N-{2-[(3R)-piperidin-3-yl]ethyl}-6-[4-(2,2,2-trifluoroethoxy)phenyl]-[2,2'-bipyridine]-4-carboxamide (I-53)Step 1. Synthesis of tert-butyl (R)-3-(2-(6-(4-(2,2,2-trifluoroethoxy)phenyl)-[2,2'-bipyridine]-4-carboxamido)ethyl)piperidine-l-carboxylate
[0342] To a stirred mixture of 6-(4-(2,2,2-trifluoroethoxy)phenyl)-[2,2'-bipyridine]-4-carboxylic acid (100 mg, 267 pmol, 1.0 eq) and tert-butyl (R)-3-(2-aminoethyl)piperidine-l-carboxylate (49 mg, 214 pmol, 0.8 eq) in ACN (1 mL) was added NMI (66 mg, 642 pmol, 3.0 eq) and TCFH (90 mg, 257 pmol, 1.2 eq) at room temperature. After stirring for 30 min at room temperature, the mixture was diluted with H2O (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-TLC (eluent of EtOAc / PE) to afford the title compound. LCMS: 585[M+H]+.Step 2. Synthesis of N-{2-[(3R)-piperidin-3-yl]ethyl}-6-[4-(2,2,2-trifluoroethoxy)phenyl]-[2,2'-bipyridine]-4-carboxamide
[0343] To a stirred mixture of tert-butyl (R)-3-(2-(6-(4-(2,2,2-trifluoroethoxy)phenyl)-[2,2'-bipyridine]-4-carboxamido)ethyl)piperidine-1-carboxylate (80 mg, 137 pmol, 1.0 eq) in DCM (1 mL) were added 2,6-lutidine (44 mg, 411 pmol, 3.0 eq) and TMSOTf (152 mg, 685 pmol, 5.0 eq) at room temperature. The mixture was stirred for 30 min at room temperature. The mixture was diluted with H2O (10 mL) and then extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (C18 column, water (10 mmol / L NH4HCO3)-ACN) to afford the title compound. LCMS: 485.20 [M+H]+.(400 MHz, DMSO-Jg) 58.99 - 8.92 (m, 1H), 8.76 - 8.75 (m, 1H), 8.69 - 8.68 (m, 1H), 8.61 - 8.59 (m, 1H), 8.33 - 8.29 (m, 3H), 8.05 - 8.01 (m, 1H), 7.54 - 7.51 (m, 1H), 7.28 - 7.25 (m, 2H), 4.90 (q, 2H), 3.92 - 3.72 (m, 1H), 3.44 - 3.35 (m, 2H), 2.97 - 2.94 (m, 1H), 2.85-2.82(m, 1H), 2.43 - 2.34 (m, 1H), 2.19- 2.14 (m, 1H), 1.85 - 1.82 (m, 1H), 1.56 - 1.30 (m, 5H), 1.09-0.96 (m, 1H).Example 9: Synthesis of rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-2-(l-methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyridine (stereoisomer 1, 1-55) and rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-2-(l-methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyridine (stereoisomer 2, 1-56)Step 1. Synthesis of cis-tert-butyl l-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinoyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate
[0344] To a stirred solution of 2-(l -methyl- lH-pyrazol-4-yl)-6-(4-(2, 2,2-trifluoroethoxy)phenyl)isonicotinic acid (250 mg, 663 pmol, 1.0 eq) and tert-butyl octahydropyrrolo[3,2-b]pyridine-4-carboxylate (150 mg, 663 pmol, 1.0eq)in ACN(1 mL) were added NMI (218 mg, 2.65 mmol, 4.0 eq) and TCFH (372 mg, 1.33 mmol, 2.0 eq) at room temperature. The resulting mixture was stirred at room temperature for 1 h. The precipitated solids were collected by filtration and washed with ACN. The solid was dried under reduced pressure to afford the title compound, which was used in the next step without further purification. LCMS: 586 [M+H]+.Step 2. Separation of cis-tert-butyl l-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-trifhioroethoxy)phenyl)isonicotinoyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (single stereoisomer, first eluting compound as stereoisomer 1) and cis-tert-butyl l-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinoyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (single stereoisomer, second eluting compound as stereoisomer 2)
[0345] cis-tert-butyl l-(2-(l-methyl-lH-pyrazoL4-yl)-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinoyl)-octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (racemic mixture) was separated by chiral HPLC to afford the title compounds. Detailed information of chiral HPLC: Preparative method - Instrument: GILSON GX-281; column: JW-CHIRALPAK ID 20 x 250mm, 5 pm; mobile phase A: EtOH: DCM=1:1, mobile phase B: Hex (0.5% 2M NH₃-MeOH): flow rate: 20 mL / min; isocratic 50 % B; wavelength: 220 / 254 nm; sample solvent: EtOH: DCM=l:l; retention time: RT1: 6.05 min (stereoisomer 1); RT2: 8.09 min (stereoisomer 2). Analytical method - Instrument: LC-93; column: CHIRALPAK ID-3, 4.6 x 50 mm, 3 pm; mobile phase A: (EtOH: DCM=l: 1 mobile phase; B: Hex (0.1% DEA); isocratic 50% B; flow: ImL / min; temperature: 25°C; UV: 254 nm; retention time: RT1: 1.609 min (stereoisomer 1); RT2: 2.234 min (stereoisomer 2)Step 3. Synthesis of rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-2-(l-methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyridine (stereoisomer 1)
[0346] To a stirred solution of cis-tert-butyl l-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-tifluoroethoxy) phenyl) isonicotinoyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (single stereoisomer, first eluting compound as stereoisomer 1) (80 mg, 137 pmol, 1.0 eq) in DCM (1 mL) were added TMSOTf (91 mg, 411 pmol, 3.0 eq) and 2,6-dimethylpyridine (73 mg, 685 pmol, 5.0 eq) at room temperature. The resulting mixture was stirred at room temperature for 3 h. The mixture was diluted with water (15 mL) and extracted with DCM (2 x 15 mL). The combined organic layers were dried over anhydrous N^SCL After filtration, the filtrate was concentrated under reduced pressure. The resulting mixture was purified by reverse phase HPLC (XBridge Prep OBD C18 column, water (10 mmol / L NH4HCO3)-ACN) to afford thetitle solid. LCMS: 486[M+H]+. ¹H NMR (400 MHz, DMSO-d₆) δ 8.45 (d, 1H), 8.24 – 8.21 (m, 2H), 8.15 (s, 1H), 7.72 (d, 1H), 7.57 (s, 1H), 7.20 – 7.18 (m, 2H), 4.87 (q, 2H), 3.92 (s, 3H), 3.88 – 3.87 (m, 0.5H), 3.76 – 3.74 (m, 0.5H), 3.59 – 3.51 (m, 1.5H), 3.40 – 3.38 (m, 0.5H), 2.81 – 2.76 (m, 0.5H), 2.68 – 2.57 (m, 1.5H), 2.47 – 2.44 (m, 1H), 2.15 – 2.12 (m, 1H), 1.86 – 1.66 (m, 2H), 1.55 – 1.33 (m, 2.5H), 1.03 – 0.93 (m, 0.5H).Example 10: Synthesis of rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-2-(l-methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyridine (stereoisomer 2)
[0347] To a stirred solution of cis-tert-butyl l-(2-(l-methyl-lH-pyrazoL4-yl)-6-(4-(2,2,2-trifluoroethoxy) phenyl)isonicotinoyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (single stereoisomer, second eluting compound as stereoisomer 2) (80 mg, 137 pmol, 1.0 eq) in DCM (1 mL) were added TMSOTf (91 mg, 411 pmol, 3.0 eq) and 2,6-dimethylpyridine (73 mg, 685 pmol, 5.0 eq) at room temperature. The resulting mixture was stirred at room temperature for 3 h. The mixture was diluted with water (15 mL) and extracted with DCM (2 x 15 mL). The combined organic layers were dried over anhydrous N^SCL. After filtration, the filtrate was concentrated under reduced pressure. The resulting mixture was purified by reverse phase HPLC (XBridge Prep OBD C18 column, water (10 mmol / L NH₄HCO₃)-ACN) to afford the title compound. LCMS: 486[M+H]+. ¹H NMR (400 MHz, DMSO-d₆) δ 8.45 (d, 1H), 8.24 – 8.21 (m, 2H), 8.15 (s, 1H), 7.72 (d, 1H), 7.57 (s, 1H), 7.21 – 7.18 (m, 2H), 4.87 (q, 2H), 3.92 (s, 3H), 3.88 – 3.87 (m, 0.5H), 3.76 – 3.74 (m, 0.5H), 3.59 – 3.51 (m, 1.5H), 3.39 – 3.38 (m, 0.5H), 2.81 – 2.76 (m, 0.5H), 2.68 – 2.57 (m, 1.5H), 2.47 – 2.44 (m, 1H), 2.15 – 2.12 (m, 1H), 1.85 – 1.66 (m, 2H), 1.55 – 1.33 (m, 2.5H), 1.03 – 0.93 (m, 0.5H).Example 11: Synthesis of rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-2-(l-methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyrimidine (single stereo-isomer, first eluting compound as stereoisomer 1, 1-112) and rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-2-(l-methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyrimidine (single stereo-isomer, second eluting compound as stereoisomer 2, 1-113)Step 1. Synthesis of cis-tert-butyl l-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-trifluoroethoxy) phenyl) pyrimidine-4-carbonyl) octahydro-4H-pyrrolo[3,2-b] pyridine-4-carboxylate
[0348] A mixture of cis-tert-butyl l-(2-chloro-6-(4-(2,2,2-trifluoroethoxy)phenyl)pyrimidine-4-carbonyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (400 mg, 740 pmol, 1.0 eq), l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (153 mg, 740 pmol, 1.0 eq), K2CO3 (306 mg, 2.22 mmol, 3.0 eq) and Pd(dppf)C12. CH2C12 (60 mg, 74 pmol, 0.1 eq) in 1,4-dioxane (4 mL) and H2O (0.4 mL) was degassed three times with N2, and then stirred for 2 h at 100°C. The mixture was allowed to cool down to room temperature, diluted with H2O (10 mL), and then was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine and dried over anhydrous N 2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (C 18 column, water (10 mmol / NH4HCO3)-ACN) to afford the title compound. LCMS: 587[M+H]+.Step 2. Synthesis of cis-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-trifhioroethoxy)phenyl)-pyrimidin-4-yl)(octahydro-lH-pyrrolo[3,2-b]pyridin-l-yl)methanone
[0349] To a stirred mixture of cis-tert-butyl l-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-trifluoroethoxy) phenyl) pyrimidine-4-carbonyl) octahydro-4H-pyrrolo[3,2-b] pyridine-4-carboxylate (280 mg, 477 pmol, 1.0 eq) in DCM (3 mL) was added TFA (0.6 mL) at room temperature. The mixture was stirred for 30 min at room temperature and then was concentrated under reduced pressure to afford the title compound, which was used in the next step directly without further purification. LCMS: 487[M+H]+.Step 3. Separation of rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-2-(l- methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyrimidine (single stereoisomer, first eluting compound as stereoisomer 1) and rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l- carbonyl]-2-(l-methyl-lH-pyrazol-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyrimidine (single stereoisomer, second eluting compound as stereoisomer 2)
[0350] Cis-(2-(l-methyl-lH-pyrazol-4-yl)-6-(4-(2,2,2-trifluoroethoxy)phenyl)pyrimidin-4-yl)(octahydro- lH-pyrrolo[3,2-b]pyridin-l-yl)methanone (racemic mixture) was separated by chiral HPLC. Detailed information of chiral HPLC: Preparative method - column: JW-CHIRALPAK IK, 20 x 250 mm, 5 pm; mobile phase A: EtOH: DCM=1:1, mobile phase B: Hex (0.5% 2M NH3-MeOH); flow rate: 20 mL / min; isocratic 60% B; wavelength: 220 / 254 nm; sample solvent: EtOH: DCM=l:l; retention time: RT1: 6.927 min (stereoisomer 1); RT2: 13.032 min (stereoisomer 2). Analytical method - Instrument: LC-93; column: CHIRALPAK IK-3, 4.6 x 50 mm, 3.0 pm; mobile phase A: (EtOH: DCM=1:1); B: Hex (0.1% DEA); isocratic 60 % B; flow: 1 mL / min; temperature: 25 °C; UV: 254 nm; retention time: RTl: 2.09 min (stereoisomer 1); RT2: 3.39 min (stereoisomer 2). LCMS: 487.20[M+H]+ / LCMS: 487.20[M+H]+. ¹H NMR (400 MHz, DMSO-d₆) δ 8.53 – 8.52 (m, 1H), 8.38 – 8.36 (m, 2H), 8.16 – 8.13 (m, 1H), 7.97 – 7.93 (m, 1H), 7.25 – 7.23 (m, 2H), 4.91 (q, 2H), 4.10 – 4.08 (m, 0.5H), 4.00 – 3.90 (m, 4H), 3.64 – 3.47 (m, 2.5H), 2.82 – 2.63 (m, 2H), 2.18 – 2.16 (m, 0.5H), 2.15 – 1.92 (m, 1.5H), 1.91 – 1.79 (m, 1.5H), 1.52 – 1.43 (m, 2H), 1.40 – 1.16 (m, 0.5H).Example 12: Synthesis of 2-(4-ethoxyphenyl)-N-[3-(piperidin-l-yl)propyl]-6-(lH-pyrazol-l- yl)pyridine-4-carboxamide (1-2)Intermediate 2-2Step 1. Synthesis of 2-(4-ethoxyphenyl)-N-[3-(piperidin-l-yl)propyl]-6-(lH-pyrazol-l-yl)pyridine-4- carboxamide
[0351] A solution of 2-chloro-6-(4-ethoxyphenyl)-N-(3-(piperidin-Lyl)propyl)isonicotinamide (40 mg, 0.1 mmol, 1.0 eq) and pyrazole (8 mg, 0.12 mmol, 1.2 eq) in DMSO (1 mL) were added CS2CO3 (97 mg, 0.30 mmol, 3.0 eq) and CmO (7 mg, 0.05 mmol, 0.5 eq) at room temperature under N2 atmosphere. The resulting mixture was stirred at 100°C for 16 h. The resulting mixture was cooled down to room temperatur e, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (C18 column, water (10 mmol NH4HCO3)- ACN) to afford the title compound. LCMS:434 [M+H]+. ¹H NMR (400 MHz, DMSO-d₆) δ 9.00 (s, 1H), 8.90 (s, 1H), 8.23 – 8.16 (m, 4H), 7.88 (s, 1H), 7.10 – 7.08 (m, 2H), 6.63 (s, 1H), 4.13 (q, 2H), 3.46 – 3.32 (m, 2H), 2.35 – 2.29 (m, 6H), 1.74 – 1.69 (m, 2H), 1.49 – 1.43 (m, 4H), 1.39 – 1.36 (m, 5H).Example 13: Synthesis of 2-(morpholin-4-yl)-N-(piperidin-4-yl)-6-[4-(2,2,2-trifluoroethoxy)-phenyl] pyridine- 4-carboxamide (1-117)Intermediate 2-3Step 1. Synthesis of tert-butyl 4-(2-morpholino-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinamido)piperidine-l-carboxylate
[0352] To a stirred solution of tert-butyl 4-(2-chloro-6-(4-(2,2,2-trifluorocthoxy)phcnyl)isonicotinamido)pipcridinc-l-carboxylatc (100 mg, 0.20 mmol, 1.0 eq) and morpholine (21 mg, 0.23 mmol, 1.2 eq) in 1,4-dioxane (2 mL) were added CS2CO3 (127 mg, 0.39 mmol, 2.0 eq), RuPhos (18 mg, 0.04 mmol, 0.2 eq) and RuPhos-Pd-G3 (33 mg, 0.04 mmol, 0.2 eq) at room temperature. The mixture was degassed three times with N2 and then stirred at 60°C for 2 h under N2. The resulting mixture was allowed to cool down to room temperature, filtered and concentrated under reduced pressure. The residue was diluted with H2O (15 mL), extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of EtOAc / PE) to afford the title compound. LCMS: 565[M+H]+.Step 2. Synthesis of 2-(morpholin-4-yl)-N-(piperidin-4-yl)-6-[4-(2,2,2-trifhioroethoxy)-phenyl]pyridine-4-carboxamide
[0353] To a stirred solution of tert-butyl 4-(2-morpholino-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinamido)piperidine-1-carboxylate (50 mg, 0.09 mmol, 1.0 eq) in DCM (1 mL) was added TFA (0.2 mL). The resulting mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in ACN and purified by reverse phase HPLC (Cl 8 column, water (0.1% NH₄HCO₃)-ACN) to afford the title compound. LCMS: 465[M+H]+. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (d, 1H), 8.18 – 8.01 (m, 2H), 7.57 (s, 1H), 7.16 (d, 2H),7.09 (s, 1H), 4.84 (q, 2H), 4.05 - 3.82 (m, 2H), 3.75 (t, 4H), 3.58 (t, 4H), 2.98 (d, 2H), 2.57 - 2.55 (m, 2H), 1.77 (d, 2H), 1.51 - 1.36 (m, 2H).Example 14: Synthesis of rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-6-(4-ethoxyphenyl)-3-fhioro-2-(l-methyl-lH-pyrazol-4-yl)pyridine (cis, single stereoisomer, 1-160)Step 1. Synthesis of tert-butyl l-(6-(4-ethoxyphenyl)-3-fluoro-2-(l-methyl-lH-pyrazol-4-yl)isonicotinoyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (cis, single stereoisomer)
[0354] To a stirred mixture of 6-(4-ethoxyphenyl)-3-fluoro-2-(l -methyl- lH-pyrazol-4-yl)isonicotinic acid (50 mg, 146 pmol, 1.0 eq) and tert-butyl octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (cis, single stereoisomer 1) (36 mg, 161 pmol, 1.1 eq) in ACN (2 niL) were added NMI (36 mg, 438 pmol, 3.0 eq) and TCFH (82 mg, 292 pmol, 2.0 eq) at room temperature. After stirring for 30 min at room temperature, the mixture was diluted with H2O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound, which was used in the next step without further purification. LCMS: 550 [M+H]+.Step 2. rel-4-[(3aR,7aR)-octahydro-lH-pyrrolo[3,2-b]pyridine-l-carbonyl]-6-(4-ethoxyphenyl)-3-fluoro-2-(l-methyl-lH-pyrazol-4-yl)pyridine (cis, single stereoisomer)
[0355] A solution of tert-butyl l-(6-(4-ethoxyphenyl)-3-fluoro-2-(l-methyl-lH-pyrazol-4-yl)isonicotinoyl)octahydro-4H-pyrrolo[3,2-b]pyridine-4-carboxylate (cis, single stereoisomer) (40 mg, 73pmol, 1.0 eq) and TFA (0.3 mL) in DCM (1.5 mL) was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (C18 column, water (10 mmol / NH₄HCO₃)-ACN) to afford the title compound. LCMS: 450.15 [M+H]+.NMR (400 MHz, DMSO-d₆) δ 8.42 – 8.36 (m, 1H), 8.15 – 7.97 (m, 3H), 7.81 – 7.60 (m, 1H), 7.09 – 7.02 (m, 2H), 4.13 – 4.08 (m, 2H), 3.95 – 3.88 (m, 3H), 3.61 – 3.48 (m, 2H), 3.42 – 3.22 (m, 2H), 2.79 – 2.66 (m, 0.5H), 2.59 – 2.53 (m, 1H), 2.36 – 2.27 (m, 1H), 2.19 – 2.11 (m, 1H), 1.89 – 1.65 (m, 2H), 1.53 – 1.29 (m, 5H), 1.05 – 0.97 (m, 0.5H).Example 15: Synthesis of 2-(oxan-4-yl)-N-(piperidin-4-yl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]pyridine-4-carboxamide TFA salt (1-131)Step 1. Synthesis of tert-butyl 4-(2-(3,6-dihydro-2H-pyran-4-yl)-6-(4-(2,2,2-trifluoroethoxy) phenyl)isonicotinamido)piperidine-l-carboxylate
[0356] To a stirred solution of tert-butyl 4-(2-chloro-6-(4-(2,2,2-tritluoroethoxy)phenyl)isonicotinamido)piperidine-l -carboxylate (100 mg, 0.20 mmol, 1.0 eq) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (49 mg, 0.23 mmol, 1.2 eq) in 1,4-dioxane (1 mL) and H2O (0.1 mL) were added K2CO3 (54 mg, 0.39 mmol, 2.0 eq) and Pd(dppf)Cl₂·CH₂Cl₂ (32 mg, 0.04 mmol, 0.2 eq) at room temperature under N2 atmosphere. After stirring at 100°C for 2 h underN2 atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of EtOAc / PE) to afford the title compound. LCMS: 562[M+H]+.Step 2. Synthesis of tert-butyl 4-(2-(tetrahydro-2H-pyran-4-yl)-6-(4-(2,2,2-trifluoroethoxy) phenyl)isonicotinamido)piperidine-l-carboxylate
[0357] To a mixture of tert-butyl 4-(2-(3,6-dihydro-2H-pyran-4-yl)-6-(4-(2,2,2-trifhioroethoxy)phenyl)isonicotinamido)piperidine-l -carboxylate (80 mg, 0.14 mmol, 1.0 eq) in MeOH (3 mL) was added Pd / C (25 mg, 5%). The resulting mixture was stirred at room temperature for 15 h under H2. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent of EtOAc / PE) to afford the title compound. LCMS: 564[M+H]+.Step 3. Synthesis of 2-(oxan-4-yl)-N-(piperidin-4-yl)-6-[4-(2,2,2-trifhioroethoxy)phenyl]pyridine-4-carboxamide TFA salt
[0358] To a stirred solution of tert-butyl 4-(2-(tetrahydro-2H-pyran-4-yl)-6-(4-(2,2,2-trifluoroethoxy)phenyl)isonicotinamido)piperidine-l -carboxylate (50 mg, 0.09 mmol, 1.0 eq) in DCM (1 mL) was added TFA (0.2 mL). The resulting mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue purified by reverse phase HPLC (Cl 8 column, water (0.1% TFA)-ACN) to afford the title compound. LCMS: 464[M+H]+. ¹H NMR (400 MHz, DMSO-d₆) δ 8.90 – 8.44 (m, 3H), 8.15 (d, 2H), 8.09 (s, 1H), 7.58 (s, 1H), 7.21 (d, 2H), 4.86 (q, 2H), 4.20 – 4.10 (m, 1H), 4.01 – 3.98 (m, 2H), 3.57 – 3.46 (m, 2H), 3.38 – 3.28 (m, 2H), 3.08 – 3.02 (m, 3H), 2.04 – 1.95 (m, 2H), 1.93 – 1.72 (m, 6H).Example 16: Synthesis of (4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-l,5-naphthyridine (stereoisomer 1, 1-154), (4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-l,5-naphthyridine (stereoisomer 2, 1-155), (4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-l,5-naphthyridine (stereoisomer 3, 1-156), and(4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-l,5-naphthyridine (stereoisomer 4, 1-157)Step 1. Synthesis of tert-butyl 5-(6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-l,5-naphthyridine-l(2H)-carboxylate
[0359] To a stirred mixture of 6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carboxylic acid (200 mg, 617 pmol, 1.0 eq) and tert-butyl octahydro-2H-l,5-naphthyridine-l-carboxylate (148 mg,617 pmol, 1.0 eq) in ACN (3 mL) were added NMI (152 mg, 1.85 mmol, 3.0 eq) and TCFH (347 mg, 1.23 mmol, 2.0 eq) at room temperature. After stirring for 1 h at room temperature, the mixture was purified byreverse phase HPLC (C18 column, water (0.1% FA)-ACN) to afford the title compound. LCMS: 547[M+H]+.Step 2. Chiral separation of tert-butyl 5-(6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-l,5-naphthyridine-l(2H)-carboxylate (single stereoisomer, first eluting compound as stereoisomer 1); tert-butyl 5-(6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-l,5-naphthyridine-l(2H)-carboxylate (single stereoisomer, second eluting compound as stereoisomer 2); tert-butyl 5-(6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-l,5-naphthyridine-l(2H)-carboxylate (single stereoisomer, third eluting compound as stereoisomer 3) and tert-butyl 5-(6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-l,5-naphthyridine-l(2H)-carboxylate (single stereoisomer, fourth eluting compound as stereoisomer 4) Tert-butyl 5-(6-(4-ethoxyphenyl)-2-( 1 -methyl- 1 H-pyrazol-4-yl)pyrimidine-4-carbonyl) octahydro- 1,5-naphthyridine- 1 (2H (-carboxylate was separated via preparative chiral HPLC (twice). Detailed information of chiral HPLC. First preparative method - Instrument: column: JW-CHIRAL ART Cellulose-SB, 20 x 250mm, 5 pm; mobile phase A: EtOH: DCM=1:1, mobile phase B: Hex (0.5% 2M NH₃-MeOH); flow rate: 20 mL / min; isocratic 90% B; wavelength: 220 / 254 nm; retention time: Peakl: 15.55 min; Peak2: 17.03 min; sample solvent: EtOH: DCM=l: 1; injection volume: 0.5 mL to afford a mixture of stereoisomers 1, 2 and 3 in Peakl. and single stereoisomer 4 in Peak2. Second preparative method Separation of stereoisomers 1, 2 and 3 (Peakl of first chiral HPLC method) - Instrument: column: JW-CHIRAL ART Cellulose-SA, 20 x 250mm, 5 pm: mobile phase A: EtOH: DCM=1:1, mobile phase B: Hex (0.5%' 2M NH₃-MeOH); flow rate: 20 mL / min; isocratic 80% B; wavelength: 220 / 254 nm; retention time: Peakl: 13.85 min (stereoisomer 1); Peak 2: 17.41 min (stereoisomer 2); Peak 3: 22.90 min (stereoisomer 3); sample solvent: EtOH: DCM=l: 1; injection volume: 0.5 mL) to afford single stereoisomer 1, single stereoisomer 2, and single stereoisomer. First analytical method - Instrument: LC-93; column: CHIRAL ART Cellulose-SB, 4.6 x 100 mm, 3.0 pm; mobile phase A: (EtOH: DCM=1: 1); B: Hex (0.1% DEA); isocratic 90 % B; flow: 1 mL / min; temperature: 25°C; UV: 254 nm; retention time: RT1: 6.993 min; RT2: 7.463 min; RT3: 9.320 min. Second analytical method - Instrument: LC-93; column: CHIRALPAK IA-3, 4.6 x 50 mm, 3.0 pm; mobile phase A: (EtOH: DCM=1: 1); B: Hex (0.1% DEA); isocratic 80 % B; flow: 1 mL / min; temperature: 25°C; UV: 254 nm; retention time: RT1: 3.411 min (single stereoisomer 1); RT2: 4.207 min (single stereoisomer 2); RT3: 5.357 min (single stereoisomer 3)
[0360] After chiral resolution: Tert-butyl 5-(6-(4-ethoxyphenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-1,5-naphthyridine-1(2H)-carboxylate, single stereoisomer, first eluting stereoisomer as stereoisomer 1,. LCMS: 547 [M+H]⁺. Tert-butyl 5-(6-(4-ethoxyphenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-1,5-naphthyridine-1(2H)-carboxylate, singlestereoisomer, second eluting stereoisomer as stereoisomer 2,. LCMS: 547 [M+H]+. Tert-butyl 5-(6-(4-ethoxyphenyl)-2-( 1 -methyl- 1 H-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro- 1, 5-naphthyridine- 1 (2H)-carboxylate, single stereoisomer, third eluting stereoisomer as stereoisomer 3,. LCMS: 547 [M+H]+. Tertbutyl 5-(6-(4-ethoxyphenyl)-2-(l-methyl-lII-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-l,5-naphthyridine-l(2H)-carboxylate, single stereoisomer, fourth eluting stereoisomer as stereoisomer 4,. LCMS: 547 [M+H]+.Step 5. Synthesis of (4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-l, 5-naphthyridine (stereoisomer 1), (4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-l, 5-naphthyridine (stereoisomer 2), (4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-1, 5-naphthyridine (stereoisomer 3), and (4aR*,8aR**)-l-[6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl]-decahydro-l, 5-naphthyridine (stereoisomer 4)
[0361] A solution of tert-butyl 5-(6-(4-ethoxyphenyl)-2-(l-methyl-lH-pyrazol-4-yl)pyrimidine-4-carbonyl)octahydro-l,5-naphthyridine-l(2H)-carboxylate (single stereoisomer, first eluting compound as stereoisomer 1) (30 mg, 55 pmol, 1.0 eq) and TFA (0.3 mL) in DCM (1.5 mL) was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure. The residue purified by reverse phase HPLC (C18 column, water (10 mmol / NH4HCO3)-ACN to afford the title compound (stereoisomer 1). LCMS: 447.20 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 1H), 8.34 - 8.31 (m, 2H), 8.10 - 8.09 (m, 1H), 7.85 - 7.79 (m, 1H), 7.10 - 7.07 (m, 2H), 4.69 - 4.31 (m, 1H), 4.14 (q, 2H), 3.94 (d, 3H), 3.65 - 3.32 (m, 1H), 3.04 - 2.78 (m, 2H), 2.64 - 2.56 (m, 2H), 2.50 - 2.41 (m, 1H), 2.11 - 1.84 (m, 2H), 1.83 - 1.80 (m, 1H), 1.68 - 1.35 (m, 7.5H), 1.03 - 1.19 (m, 0.5H).
[0362] Stereoisomer 2 was prepared analogously to stereoisomer 1 above. The residue was purified by reverse phase HPLC (C18 column, water (10 mmol / NH4HCO3)-ACN to afford the title compound (stereoisomer 2). LCMS: 447.20 [M+H]+. ‘H NMR (400 MHz, DMSO-(fc) 58.48 (s, 1H), 8.33 - 8.31 (m, 2H), 8.11 (s, 1H), 7.80 (s, 1H), 7.09 - 7.07 (m, 2H), 4.14 (q, 2H), 3.93 (s, 3H), 3.31 - 3.25 (m, 3H), 2.90 - 2.87 (m, 1H), 2.76 -2.67 (m, 1H), 2.33 - 2.28 (m, 1H), 1.90 - 1.55 (m, 5H), 1.54- 1.19 (m, 6H).
[0363] Stereoisomer 3 was prepared analogously to stereoisomer 1 above.. The residue was purified by reverse phase HPLC (C18 column, water (10 mmol / NH4HC03)-ACN) to afford the title compound (stereoisomer 3). LCMS: 447.20 [M+H]+. ‘II NMR (400 MHz, DMSO-(fc) 88.48 (s, 1H), 8.33 - 8.31 (m, 2H), 8.11 (s, 1H), 7.80 (s, 1H), 7.09 - 7.07 (m, 2H), 4.14 (q, 2H), 3.93 (s, 3H), 3.31 - 3.25 (m, 3H), 2.90 - 2.87 (m, 1H), 2.76 -2.67 (m, 1H), 2.33 - 2.28 (m, 1H), 1.90 - 1.55 (m, 5H), 1.54- 1.19 (m, 6H).
[0364] Stereoisomer 4 was prepared analogously to stereoisomer 1 above. The residue was purified by reverse phase HPLC (C18 column, water (10 mmol / NH4HC03)-ACN) to afford the title compound (stereoisomer 4). LCMS: 447.20 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 1H), 8.34 - 8.31 (m,2H), 8.11 - 8.10 (m, 1H), 7.85 - 7.79 (m, 1H), 7.10 - 7.08 (m, 2H), 4.69 -4.35 (m, 1H), 4.14 (q, 2H), 3.94 (d, 3H), 3.65 - 3.32 (m, 1H), 3.04 - 2.57 (m, 4H), 2.50 - 2.34 (m, 1H), 2.13 - 1.90 (m, 2H), 1.83 - 1.80 (m, 1H), 1.68 - 1.35 (m, 7.5H), 1.03 - 1.19 (m, 0.5H).
[0365] The following compounds in Table 2 were prepared according to methods analogous to those mentioned above.
[0366] Table 2. LCMS Data for Further CompoundsExample 17: Biochemical AssaysTASL-Hibit degradation assay in HEK293T cells
[0367] HEK293T cells were engineered to stably-express HiBit tagged human TASL (TLR Adaptor Interacting With Endolysosomal SLC15A4) and human SLC15A4 (Solute Carrier Family 15 Member 4). An optimized engineered single clone cell line was identified and used for all studies, and routinely cultured in DMEM+10% hFBS+1% penicillin-streptomycin + 500 pg / mL hygromycin B and 1 pg / mL puromycin in a T75 flask. For determining the half-maximal effective concentration (EC50) of test compounds on TASL degradation, 4000 cells were distributed in a total volume of 40uL to a 384-well plate (Corning 3570) and recovered overnight in a 37°C & 5% CO2 incubator. Test compounds were dissolved in DMSO, serially-diluted in a 384-LDV plate, and then 40nl of diluted compounds were transferred to the 384-well test plate by Echo 655. Each compound was dispensed in duplicate and the final DMSO concentration was 0.1%.The assay plate was then incubated for 6 hours in a 37 °C & 5% CO2 incubator. After 6 hours treatment, Hibit luminescence signal was determined by LABTECH microplate reader. EC50 and Y values (% degradation) were determined by normalized Hibit signal to the max signal at 6H with and without 10um reference compound treatment and curve fit with XLift.ISG reporter and IFN-P ELISA assay in THPl-dual cells
[0368] THPl-Dual™ Cells (InvivoGen, thpd-nfis) were maintained under 1x10^6 cells / ml density in T75 flask with RPMI 1640+10% hFBS+1% Penicillin-streptomycin + 10 pg / mL of Blasticidin and 100 ug / ml of Zeocin. Compound source plates were prepared as described above. To prepare for the ISG reporter assay, 40000 THPl-Dual™ cells were transferred to a 384-well culture plate (corning 3764) in a final volume of 40 pL culture medium (RPMI 1640+10% hFBS+1% Penicillin-streptomycin).Test compounds were dissolved in DMSO, serially diluted in a 384-LDV plate, and then 40nl of diluted compounds were transferred to the 384-well test plate by Echo 655. The test plate was incubated for 30 minutes, followed by addition of 40 nL R848 (Resiquimod, MCE HY- 13740) to a final concentration of 30uM, and then incubated for 24 hours in an incubator at 37°C & 5% CO2.10 pL / well of culture medium was then collected and transferred to a 384-well test plate (Corning 3570), 25 pL / well QUANTI-Luc™ Gold detection buffer was added, and luminescence signal was detected by microplate reader.
[0369] For the IFN-P ELISA assay, human IFN-p Valukine ELISA (R& D, VAL137) was used to quantify secreted IFN-p. 100,000 THPl-Dual™ cells in culture medium (RPMI 1640+10% hFBS+1% Penicillin-streptomycin ) were seeded in a 96-well plate in a total volume of 100 pL and then recovered for 20 hours at 37°C & 5% CO2. 5 pl of test compound was added to each well to reach the desired final concentration and incubated for 30 minutes. Cells were then stimulated by 30uM R848 for 32 hours at 37°C & 5% CO2.50 pL / well of culture supernatant was collected and IFN- was quantified based on the manufacturer’s instructions.
[0370] Table 3 shows the EC50 and IC50 of selected compounds of this disclosure in the above assays. Compound activity designations have the following values: A (< 10 nM); B (10 nM to < 100 nM); C (100 nM to < 1000 nM); D (> 1000 nM); and (not tested).Table 3. Biochemical Assay ResultsEQUIVALENTS
[0371] The disclosure may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the disclosure described herein. Scope of the disclosure is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
Claims
CLAIMSWe Claim:
1. A compound of formula I:Ior a pharmaceutically acceptable salt thereof, wherein:R1is halogen, alkoxy, C3-7cycloalkoxy, haloalkoxy, a C3-7 cycloalkyl, phenyl, cubanyl, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a C5-12 bridged bicyclic carbocyclic ring, or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein each R1is optionally substituted with q instances of R9;q is 0, 1, 2, 3, or 4;each R9is independently hydrogen, halogen, -CN, -OR, oxo, -N(R)2, - C(R)2OR, -S(O)2NR2, -C(O)N(R)2, -C(R)2C(O)N(R)2or an optionally substituted group selected from C1-6 aliphatic, C1-5cycloalkyl, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Z1is CR2or N; Z2is CR2or N; where at least one of Z1or Z2is not N;R2is hydrogen, halogen, -N(R)2, -OR, or optionally substituted C1-6aliphatic;Ring B is selected from cubanyl, pyridinone, pyrazolopyridine, indazole, a 5-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-12 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orwherein Ring B together with substituent R3is selected from; wherein:X1, X2, X3, and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;Xsis C or N;X9is C or N;R3is an optionally substituted group selected from C3-6aliphatic; C2-6alkoxy; C3-C6cycloalkyloxy; chlorodifluoromethoxy; cycloalkyl substituted methoxy; a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 4-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with s occurrences of R3A;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4taken together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur;each R3Ais independently halogen, OR, C3-6cycloalkyl or a mono- or di-C2-6alkyl amino;s is 0, 1, 2, 3, 4, or 5t is 0, 1, 2, 3, or 4;R5is optionally substituted C1-6aliphatic;R6is L-R7; orR5and R6taken together with the nitrogen atom to which they are attached form a 5-7-membered saturated or partially unsaturated monocyclic heterocycle or 8-12-membered saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8;L is a covalent bond or an optionally substituted C1-8bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one, two, three, four, or five methylene units of the chain are optionally and independently replaced by –C(R)2-, -Cy-, –N(R)-, -O-, C(O)-, -S-, -S(O)- or –S(O)2-;each -Cy- is independently an optionally substituted group selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered satur ated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each R7is independently hydrogen, halogen, -N(R)2, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R,-C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R8is independently hydrogen, halogen, -N(R)2, oxo, -C(R)2N(R)2, -C(R)2C(R)2N(R)2, -CN, -OR, - C(R)2OR, -C(R)2C(R)2OR, -SR, -S(O)2R, -S(O)2N(R)2, -S(O)R, -S(O)N(R)2, -C(O)R, -C(O)N(R)2, - C(R)2C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)N(R)2, -N(R)C(NR)N(R)2, -N(R)N(R)2, -N(R)S(O)2N(R)2, -N(R)S(O)2R, -N=S(O)(R)2, -S(NR)(O)R, -N(R)S(O)R, or an optionally substituted group selected from C1-8aliphatic, C1-C8haloalkyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 memberedsaturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6- 11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; ortwo R8together with the atom(s) to which they are attached form a 3-7-membered spiro, fused, or bridged saturated or partially unsaturated monocyclic carbocyclic ring;u is 0, 1, 2, 3, 4, or 5;each R is independently hydrogen, -CN, halogen, or an optionally substituted group selected from Ci-6 aliphatic; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- 10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-10 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-11 membered saturated or partially unsaturated fused bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; ortwo R groups on the same carbon or nitrogen are taken together to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-11 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
2. The compound of claim 1, wherein:Ring B is selected from a 6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring B is optionally substituted with t instances of R4; orRing B together with substituent R3iswherein:X1, X2, X3, and X4are each independently selected from CR4and N;X5is CR4, NR, N, O, or S;X6and X7are each independently selected from CR4, NR, N, O, and S;each R4is independently hydrogen, -OR, halogen, or C1-4aliphatic; orR3and one occurrence of R4taken together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur; andt is 0, 1, 2, 3, or 4.
3. The compound of claim 1 or 2, wherein:Ring B together with substituent R3iswherein:at least one of X3, X6, or X7is N; orat least one of X3, X6, or X7is O; orat least one of X5, X6, or X7is S; orX5is S, X6is N, and X7is CR4; orX5is CR4, X6is NR, and X7is N; orX5is CR4, X6is N, and X7is CR4; orX5is NR, X6is N, and X7is NR; orX5is CR4, X6is S, and X7is CR4; orX5is O, X6is N, and X7is CR4.
4. The compound of any one of claims 1-3, wherein Ring B together with substituent R3is selected from5. The compound of any one of claims 1-4, wherein R1is selected from:
7. The compound of any one of claims 1-6, wherein q is 1.
8. The compound of any one of claims 1-6, wherein q is 0.
9. The compound of any one of claims 1-7, wherein each R9is independently halogen, -OR, -N(R)2, optionally substituted Ci-6 aliphatic or optionally substituted C3-6cycloalkyl.
10. The compound of any one of claims 1-7, wherein each R9is independently fluoro, chloro, -OMe, -OEt, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, -CN or -NH2.
11. The compound of any one of claims 1-5, wherein12. The compound of any one of claims 1-5 or 11, wherein R9is optionally substituted C1-6aliphatic or optionally substituted C3-6cycloalkyl.
13. The compound of any one of claims 1-12, wherein Z1is CR1and Z2is CR2or N.
14. The compound of any one of claims 1-12, wherein Z1is CR2or N and Z2is CR1.
15. The compound of any one of claims 1-14, wherein R5and R6taken together with the nitrogen atom to which they are attached form a saturated or partially unsaturated 5-7-membered monocyclic heterocycle or saturated or 8-12-membered partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle optionally substituted with u occurrences of R8.
16. The compound of claim 15, wherein u is 0, 1, or 2.
17. The compound of claim 15 or 16, wherein the group -N(R5)(R6) is selected from18. The compound of claim 17, wherein the group -N(R5)(R6) is selected from:
19. The compound of claim 19, wherein the group -N(R5)(R6) is selected from:
20. The compound of any one of claims 1-19, wherein R2is hydrogen.
21. The compound of any one of claims 1-19, wherein R2is halogen, optionally substituted C1-6aliphatic, -N(R)2or -OR.
22. The compound of any one of claims 1-21 wherein the compound is selected from any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.
23. The compound of any one of claims 1-21 of any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.
24. The compound of any one of claims 1-21 of any one of the following formulae:or a pharmaceutically acceptable salt of any of the foregoing.
25. The compound of any one of claims 1-21 of any one of the following formulae:or a pharmaceutically acceptable salt thereof.
26. The compound of any one of claims 1-25, having a structure of:whereinR1is phenyl, isoxazolyl, or pyrazolyl, R1is optionally substituted with q instances of R9;q is 0, 1 or 2;Ring B is phenyl, pyridyl, or cyclohexyl, and is substituted with R3and with t instances of R4;t is 0, 1 or 2;Z1is CH or N;R5and R6taken together with the nitrogen atom to which they are attached form a 5- to 7-memebred saturated or partially unsaturated monocyclic heterocycle or 8- to 12-membered saturated or partially unsaturated fused, bridged, or spiro bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, andu is 0, 1, 2, 3, or 4.
27. The compound of claims 26, wherein Ring B and any substituents have a structure of28. The compound of claim 27, wherein Ring B and any substituents have a structure of29. The compound of any one of claims 26 to 28, whereinhas a structure ofHN—The compound of claim 29, whereinhas a structure of31. The compound of any one of claims 26 to 30, wherein R1has a structure of33. The compound of claim 26, having a structure of:R1is phenyl or pyrazolyl substituted with 0 or1 R9;R5and R6taken together with the nitrogen atom to which they are attached form a 8- to 12-membered saturated fused bicyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 0, 1, 2, or 3.
34. The compound of claim 26, having a structure of:X2is N or CH;R1is isoxazolyl or pyrazolyl substituted with 1 R9;R5and R6taken together with the nitrogen atom to which they are attached form a 5- to7-membered saturated monocyclic heterocycle having 0, 1, or 2 additional ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, the heterocycle substituted with u occurrences of R8, and u is 1 or 2.
35. The compound of claim 26, having a structure of:(lie),whereinRing B is pyridyl or phenyl:R1is pyrazolyl or isoxazolyl substituted with 1 R9, andu is 1 or 2.
36. The compound of claim 26, having a structure of:whereinRing B is cyclohexyl;R1is phenyl or pyrazolyl substituted with 0 or 1 R9; andu is 1, 2, or 3.
37. The compound of any one of claims 26 to 36, wherein R9is absent, methyl or fluoro.
38. The compound of any one of claims 26 to 37, wherein R3is ethoxy.
39. The compound of any one of claims 26 to 38, wherein at least one R8is methyl.
40. The compound of any one of claims 26 to 39, wherein at least one R8is N(R)2and at least one R is H.
41. The compound of any one of the claims 1-40, wherein the compound is selected from those depicted in Table 1, or a pharmaceutically acceptable salt thereof.
42. The compound selected from those depicted in Table Al, or a pharmaceutically acceptable salt thereof.
43. The compound of claim 41, wherein the compound is selected from 1-151, 1-165, 1-282, 1-283, 1-293, 1-309, and 1-350 or a pharmaceutically acceptable salt thereof.
44. A pharmaceutical composition comprising a compound according to any one of claims 1-43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
45. The compound of any one of claims 1-43, or the pharmaceutical composition of claim 44, for use as a medicament.
46. A method of inhibiting SLC in a biological sample, comprising contacting the sample with the compound of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 44.
47. A method of treating an SLC-mediated disorder, disease, or condition in a patient, comprising administering to said patient the compound of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 44.
48. The method of claim 47, wherein the SLC-mediated disorder, disease, or condition is an autoimmune disorder, disease, or condition.
49. The method of claim 47, wherein the SLC-mediated disorder, disease, or condition is an inflammatory disorder, disease, or condition.
50. The method of claim 48 or 49, wherein the SLC-mediated disorder, disease, or condition is selected from Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, Graves' Disease, Hashimoto's thyroiditis, myasthenia gravis, type 1 diabetes mellitus, Multiple Sclerosis (MS), pemphigus vulgaris, Antiphospholipid Syndrome (APS), granulomatosis with polyangiitis (Wegener's Granulomatosis), eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome), dermatomyositis, polymyositis, systemic sclerosis (scleroderma), ankylosing spondylitis, ulcerative colitis, crohn's disease, celiac disease, vitiligo atopic dermatitis, psoriasis, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, lupus nephritis, pernicious anemia, sclerosing cholangitis, infectious mononucleosis, B-cell lymphomas, chronic fatigue syndrome / myalgic encephalomyelitis, Aicardi-Goutières Syndrome (AGS ), spondyloenchondrodysplasia with immune dysregulation, STING-Associated Vasculopathy with Onset in Infancy (SAVI), Japanese Autoinflammatory Syndrome with Lipodystrophy (JASL), Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature (CANDLE), ubiquitin-specific peptidase 18 (USP18) deficiency, PNPT1-associated mitochondrial disease, SAMHD1-associated interferonopathy, ADAR1-associated interferonopathy, systemic lupus erythematosis, lupus nephritis, cutaneous lupus, Cryopyrin- Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis, metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, autoimmune pancreatitis (AIP), type I diabetesmellitus, antiphospholipid syndrome (APS), sclerosing cholangitis, systemic onset arthritis, irritable bowel disease (IBD), pemphigus vulgaris, pemphigus foliaceus, autoimmune hepatitis, hypopituitarism, graft-versus-host disease (GvHD), autoimmune skin diseases, uveitis, pernicious anemia, and hypoparathyroidism, polyangiitis overlap syndrome, Kawasaki's disease, sarcoidosis, lomerulonephritis, cryopathies, Cutaneous Lupus (CLE), hidradenitis suppurativa, Blau syndrome, lung fibrosis, asthma, graft versus host disease, allograft rejection, inflammatory bowel disease, psoriasiform dermatitis, endosomal TLR-dependent inflammation, endosomal TLR-induced hyperinflammation, macrophage activation syndrome, allergic airway inflammation, sarcoidosis, sepsis, septic shock, Shigellosis, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HIV infection and CMV retinitis, AIDS, hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), ARC or malignancy, herpes, Waldenstrom’s Macroglobulinemia (WM), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), cutaneous diffuse large B cell lymphoma, and primary CNS lymphoma, Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury, pancreatitis (acute or chronic), allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, chronic thyroiditis, autoimmune gastritis, diabetes, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic β-cell disease, diseases characterized by massive neutrophil infiltration, rheumatoid spondylitis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, keloid formation, scar tissue formation, pyresis, influenza, angiogenic disorders including solid tumors, ocular neovasculization, infantile haemangiomas, stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hypoxia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia, toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris.
